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ABSTRACT 
The current retrospective study examined the treatment effectiveness of a residential 
treatment center (RTC) for adolescent males using a psychotropic medication reduction 
protocol. Of 226 participants 64% were admitted on medication, with 69% of those on multiple 
medications. At admission, those on medication endorsed more emotional and behavioral 
symptoms. Those admitted without medication had better program compliance. Two-thirds of 
those admitted on medication had all medications discontinued. The majority remaining on 
medication had a decrease in number of medications. At discharge and follow up periods, all 
participants, regardless of medication status, generally fared equally, lending support for the 
RTC program and its use of the medication protocol. Implications and suggestions for future 
research are included. 
KEYWORDS: adolescent, residential treatment center, medication, medication reduction, 
concomitant medication, treatment effectiveness, adolescent psychiatry 
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INTRODUCTION 
As defined by the surgeon general, “A residential treatment center (RTC) is a licensed 
24-hour facility (although not licensed as a hospital), which offers mental health treatment” 
(Mental Health: A Report of the Surgeon General, 1999).  This type of placement is 
commonplace for children and adolescents whose behavioral, emotional, and psychiatric needs 
have been deemed too complex for traditional outpatient treatments. RTCs provide treatment 
providers with an opportunity to work with these youth in a highly structured and supervised 
setting over a prolonged period the time. Additionally, the clinical complexity of these clients 
often results in the use of psychotropic medications as part of treatment. However, RTC clients 
appear to be prescribed medications at a rate much higher than that found in outpatient 
settings (Breland-Noble et al, 2004). Yet despite the frequency of use there is very little research 
on the efficacy of psychotropic medications on children and adolescents in general, and almost 
no research on the unique RTC population specifically (Thomas & Penn, 2002). In addition to 
questions about effectiveness there are also concerns about the safety of these medications, 
including concerns about side-effects and the impact on long-term development.  
Many in the field of psychiatry have suggested providers make more efforts to observe 
clients removed from all medications for a period of time to better determine the clients’ 
baseline functioning before providing any medication (Thomas & Penn, 2002) to better evaluate 
and determine the necessity of pharmacological treatment. The purpose of the present study is 
to evaluate this type of medication protocol used at an RTC.  The focus of this study is to 
evaluate the effectiveness of the medication protocol in reducing the use of medications in RTC 
clients and comparing the overall RTC effectiveness for those clients who were re-prescribed 
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medication, had their medication permanently discontinued, and those who were never on 
medication.  
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REVIEW OF THE LITERATURE 
Prevalence Rates 
Clients in Residential Treatment 
Determining the actual number of children and adolescents placed in RTCs is difficult, 
but this type of placement appears to be on the rise (Underwood, Barretti, Storms, & Safonte-
Strumolo, 2004).  This is likely due in part to the deinstitutionalization movement of recent 
decades which has resulted in less utilization of inpatient psychiatric hospitals (Connor, Doerfler, 
Toscano, Volungis, & Steingard, 2004; Underwood et al., 2004).  According to Warner and 
Pottick (2003) approximately 66,000 children and adolescents are placed in RTCs.  Burns, 
Hoagwood, and Maultsby (1998) suggest that 8% of children and adolescents who receive 
mental health treatment do so in RTCs.  Evaluation of RTCs from across the United States of 
America suggest that the majority of youth in RTCs are male (61%), between the ages of 13 and 
17 (75%), and White (65%; compared to 21% Black and 12% Hispanic). Most adolescents placed 
in RTCs are referred from either a social service agency (37%) or the juvenile court system (27%; 
Warner & Pottick).  
The number of adolescents in RTCS is separate from adjudicated adolescents placed in 
juvenile residential correctional facilities, which according to the Census of Juveniles in 
Residential Placement (CJRP) totaled 92, 854 in 2006 (The Office of Juvenile Justice and 
Delinquency Prevention; OJJDP). However, many of the adolescents placed in RTCs are 
adjudicated and were provided an RTC placement in lieu of a correctional facility. Distinguishing 
these delinquent and non-delinquent adolescent populations is extremely challenging 
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considering the hefty overlap between mental health problems and criminal activity. It is 
estimated that up to 60% of adolescents residing in a juvenile correctional facility suffer from at 
least one mental health disorder (Underwood et al., 2004) and, conversely, almost all 
adolescents placed in RTCs have had some involvement with the legal system (Sukhodolsky & 
Ruchkin, 2006).   
Diagnoses in RTC Clients 
In addition to criminal behavior, adolescents placed in RTCs generally exhibit severe 
emotional and behavioral problems.  In the general population it is estimated that 15% to 21% 
of children and adolescents suffer from at least one psychological disorder (Underwood et al., 
2004; Vermeiren, Jespers, & Moffitt, 2006). The prevalence rates are significantly higher in RTC 
settings. In a survey of 95 adolescent facilities, 73% of youth had “mental health problems”, with 
57% having received previous mental health treatment. Another study found that up to 77% of 
juvenile delinquents met criteria for a mental health disorder (Thomas & Penn, 2002).  
Comorbidity, defined as having two or more psychological diagnoses, has been found in over 
half of RTC youth with depression and anxiety disorders co-occurring in 70%, and depressive and 
disruptive behavior disorders co-occurring in 50% (Vermeiren et al., 2006).  Connor et al. (2004) 
published results from a study conducted at an RTC where 92% of the adolescents admitted to 
the facility between 1994 and 2001 received at least one psychiatric diagnosis, 39% received 
two diagnoses, 32% had three diagnoses, and 20% had four diagnoses. Warner et al. (2004) 
found that 44% of youth in RTCs had at least two diagnoses.  
Several different diagnoses are prevalent in the RTC population. Not surprisingly, many 
adolescents in residential settings are diagnosed with Conduct Disorder. It has been estimated 
that anywhere from 30% to 90% of the RTC population meet criteria for this diagnosis (Thomas 
& Penn, 2002). Depression is estimated to occur in 8% of adolescents in the general population 
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(Shoaf, 2004) whereas mood disorders range from 7% to 42% in RTC populations. Substance use 
disorders have been estimated to be present in approximately 62% of the RTC population, 
Attention Deficit/Hyperactive Disorder (ADHD) in 7% to 46%, and anxiety disorders in 8% to 36% 
(Garland et al., 2001; Thomas & Penn, 2002). 
In delinquent populations, mood disorders are estimated to occur in 11% to 33% 
(Vermeiren, 2003) and Posttraumatic Stress Disorder (PTSD) in 2% to 13% of delinquent 
(Sukhodolsky & Ruchkin, 2006), with one study finding PTSD present in 32% of incarcerated 
adolescents (Steiner, Garcia, & Matthews, 1997). Even if PTSD is not diagnosed, traumatic 
histories are common for a large number of adolescents in out-of-home placements. For 
example, Connor et al. (2004) found that 47% of the RTC participants in their study had been 
physically abused.   
Psychotropic Medications in the General Pediatric Population 
Over the last several years there has been a dramatic increase in the use of 
psychopharmacological interventions for children and adolescents.  Several studies have 
demonstrated that this age group represents one of the highest rates of increase in 
psychotropic use (Thomas, Conrad, Casler, & Goodman, 2006). One study found that of the 
nearly 35 million youth who visited an outpatient provider for mental health related concerns in 
the years 2000 and 2001, nearly 3 million (8.3%) were prescribed a psychotropic medication 
(10% for males). Although that number may not seem overwhelming, it represents a 191.7% 
increase in prescription rates compared to 1994 (Thomas et al., 2006). Safer, Magno Zito, and 
desReis (2003) cited national reviews of HMO and Medicaid databases that showed a 4- to 10-
fold increase for antidepressants, a 36- to 153-fold increase for alpha agonists (e.g., 
antihypertensives, sedatives), and a 3- to 7-fold increase in stimulants between the years of 
1987 and 1996; similar increases were noted for neuroleptics.  
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The high rates of psychtropic medication use for youth have been well documented 
across multiple reviews. A 1994 chart review of child psychiatrists at a university-based 
outpatient clinic found prescription rates ranging from 15% to 19%, with concurrent (i.e., 
multiple) medication rates ranging from 11% to 22%. The most common medication classes 
were stimulants (35% to 51%), neuroleptics (18% to 37%), and antidepressants (24% to 26%; 
Kaplan, Simms, & Busner, 1994). More recently, a study conducted on the prescribing patterns 
of child psychiatrists in New York found that, on one day in 2002, 74% of children and 
adolescents who visited one of eight outpatient clinics received psychotropic medication and 
50% received prescriptions for two or more medications (Staller, Wade, & Baker, 2005). Another 
study found that 1 in 10 adolescent males who presented for psychiatric consultation with a 
prescribing physician were given a prescription for a psychotropic medication. A concerning 
finding from that study was that up to 26% of adolescents who were prescribed psychotropic 
medications were not given an associated mental health diagnosis (Ringel & Sturm, 2001). In 
2002, over 10 million antidepressant medications were written for children and adolescents in 
the United States (Antonuccio, 2008). It appears that the best current estimate of overall 
psychotropic medication use for children and adolescents is between 5% and 15% (Handwerk, 
Smith, Thompson, Spellman, & Daly, 2008). Of adolescents ages 12 to 17, the estimate is roughly 
6% (Ringel & Sturm, 2001; Simpson, Cohen, Pastor, & Reuben, 2008).  
The practice of prescribing multiple psychotropic medications is common and increasing 
(Safer et al., 2003). Overall, leaders in the field of child psychiatry continue to support the use of 
concomitant medication use for specific indications. Yet, despite the warning of the Council of 
the American Academy of Child and Adolescent Psychiatry to use concomitant medications 
cautiously and judiciously rates remain high (Safer et al., 2003). Increases in concomitant 
medication use were found to range anywhere from 4% to 133% during the 1990s (Safer et al.). 
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Rates of concomitant medications in outpatient treatment ranged from 25% to 68% for clients 
with Attention-Deficit/Hyperactivity Disorder (ADHD; Safer et al.), 39% for Obsessive Compulsive 
Disorder (OCD; Geller, Biederman, Reed, Spencer, & Wilens, 1995), and 71% for Bipolar Disorder 
(Biederman et al., 1998), with one study finding an average of 3.2 psychotropic medications for 
children and adolescents diagnosed with Bipolar Disorder (Bhangoo et al., 2003). Kumra et al. 
(1996) found that adolescents diagnosed with Schizophrenia were prescribed a mean of 2.1 
psychotropic medications.  Concomitant rates were found to range from 17% to 20% for 
students in special education classrooms (Safer et al., 2003), 45% for youth in foster care (Zima, 
Bussing, Creculius, Kaufman, & Belin, 1999), and 52% for children considered wards of the state 
(Anderson, Naylor, Kruesi, & Stoewe, 2002; cited in Safer et al., 2003). Several studies reviewed 
by Safer et al. (2003) found that the antihypertensive clonidine and methylphenidate were the 
most common medication combination for children and adolescents. Stimulants and 
antidepressants were found to be an especially common combination for youth with aggression 
problems.  Pathiyal , Miwa, Sverdiov, Gardner, and Jones (1998; cited in Safer et al., 2003) found 
that 22% of clients prescribed methylphenidate (e.g., Ritalin) were also prescribed an 
antidepressant. Conversely, 30% to 33% of youth prescribed an antidepressant also received a 
stimulant (Rushton & Whitmire, 2001; Zito et al., 2002).  
Psychotropic Medications in RTCs 
Although the rates of psychotropic medication use in the general youth population is 
high, the prevalence in out-of-home placements is staggering. Najjar et al. (2004) conducted a 
study of children and adolescents in an inpatient treatment facility during two distinct time 
periods. The researchers found that in 1991 14% of clients were admitted on psychotropic 
medications and 40% were discharged on medications. In 1998 46% were admitted on 
medications and 75% were discharged on medication. A study published in 1994 examined the 
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medication use at four state-run inpatient hospitals and found a prevalence rate of 98% (Zito, 
Craig, & Wanderling, 1994). 
 Connor, Ozbayrak, Harrison, and Melloni (1998) evaluated the medication utilization at 
an RTC. The study included 83 children with a mean age of 14, mostly male, Caucasian, and a 
mean full scale IQ score of 78. The researchers found that 76% of the adolescents were receiving 
medications at admission, with 40% receiving two or more medications. Furthermore, a chart 
review revealed that 57% of the total sample had received at least one trial of multiple 
medications prior to admission. The most common medications were neuroleptics (35%), 
followed by sedative-hypnotics (26%), antidepressants (22%), mood stabilizers (16%), 
anticonvulsants alone (14%), and antihypertensives (7.2%). The authors noted that the 
prevalence of these medications was greater than the prevalence of their diagnostic indications, 
suggesting a large degree of off-label prescribing (i.e., for an unapproved use). The chart review 
of past multiple medication trials revealed an average of 1.9 medications with 52% taking two 
medications, 29% taking three, 11% taking four, and nearly 8% taking five medications. The most 
common medication combination was a neuroleptic and lithium (26%) followed by a neuroleptic 
and antidepressant (19%).   
In a study done in Tennessee in 2004, 40% of adolescents (ages 13 to 18) in state 
custody were taking at least one prescription medication. The study also found that 65% of 
children and adolescents placed in residential treatment facilities were prescribed psychotropic 
medication; this percentage was significantly higher than other types of placements such as 
group and foster homes (Bellonci & Henwood, 2006).  However, another study found that 
approximately 67% of youth in therapeutic foster homes and 77% of youth in group homes took 
psychotropic medications (Breland-Noble et al., 2004). A review of Medicaid files in 
Connetecitut revealed that youth taking psychotopic medication were more likely to be in state 
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custody, male, and less likely to be African American or Hispanic (Martin, Van Hoof, Stubbe, 
Sherwin, & Scahill, 2003).  
Warner et al. (2004) published a comprehensive study on the use of prescribed 
psychotropic medications among youths involved in the adolescent mental health system (which 
included inpatient, community outpatient, and residential treatment facilities). They found that 
approximately one-third of all youths in the system were prescribed a psychotropic medication. 
The rates of medication usage were highest in inpatient settings (76%), followed by residential 
centers (59%). This study found that 13.9% of youth who were prescribed psychotropic 
medications were apparently not given any mental health diagnosis.  The study also found that 
nearly 29% of youths with one diagnosis and 40% of youths with two diagnoses were prescribed 
psychotropic medication. The most common diagnosis for youth taking medication was ADHD, 
followed in order by Conduct Disorder, Adjustment Disorder, mood disorders, and anxiety 
disorders. The researchers also investigated the percentage of youth taking medication based 
on diagnosis: 66% with psychotic disorders, 52% with ADHD, 44.5% with a mood disorder, 32% 
with an anxiety disorder, and 28% with Conduct Disorder. Sixty-seven percent of youth dually 
diagnosed with ADHD and an anxiety disorder and 57% of youth dually diagnosed with ADHD 
and Conduct Disorder were prescribed at least one psychotropic medication. 
The actual number of adolescents in RTC treatment receiving pharmacological 
intervention is difficult to determine. However, it appears the best overall estimate is that two-
thirds to three-fourths of youth in RTCs are prescribed at least one psychotropic medication 
(Breland-Noble et al., 2004; Warner et al., 2004). 
 
 
 
10 
 
Treatment Effectiveness 
Residential Treatment Centers 
The RTC population is a diverse and clinically complex population that presents many 
challenges for treatment. Studying the treatment effectiveness of RTCs is also difficult. Several 
studies have been published on the effectiveness of residential treatment centers, although it is 
often difficult to make comparisons as the outcome criteria used vary dramatically. Some 
studies have been focused on specific symptoms and disorders. For example, Rohde et al. (2004) 
conducted a study evaluating the effectiveness of a CBT-based RTC for 93 adolescents dually 
diagnosed with Major Depressive Disorder and Conduct Disorder. The treatment consisted of 
common CBT components such as mood monitoring, behavioral activation, relaxation, cognitive 
restructuring, communication, and conflict resolution. Results indicated that at posttest 39% of 
adolescents in the CBT group displayed significant decreases in depressive symptoms (compared 
to 19% of adolescents in a skills-group). However, these symptom reductions were not 
maintained at 6- and 12-month follow ups. Ahrens and Rexford (2002) evaluated a brief group 
intervention for juveniles in an RTC diagnosed with PTSD. Four weeks following the intervention, 
the participants demonstrated reductions in depressive and PTSD symptoms compared to a 
waitlist control group.   
Lyons, Terry, Martinovich, Peterson, and Bouska (2001) conducted a 2-year multisite 
longitudinal study with 285 adolescents involved in residential treatment. The researchers 
evaluated multiple areas of treatment effectiveness including psychological symptom 
presentation and risk behaviors. Results indicated that, in general, residential treatment was 
effective at reducing risk behaviors, reducing symptoms of depression, and improving 
management of psychosis.  However, there was no clear indication that the RTCs were 
particularly effective at improving overall functioning. Furthermore, the researchers found some 
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evidence to suggest that adolescents placed in RTCs may experience increased levels of anxiety 
and hyperactivity. The researchers suggested that the RTCs were somewhat more effective at 
treating emotional disorders (such as PTSD) as opposed to more behavioral disorders (such as 
Conduct Disorder).  This research contained no follow-up study and specific treatment 
components were not discussed.  
Other studies have focused on functioning after discharge from RTCs, dating back as 
early as the 1970s. Weinstein (1974) reviewed the effects of an RTC for 122 adolescent males. 
The researcher gathered data at admission, discharge, and 6- and 18-month follow ups. The 
study also included a comparison group of untreated adolescents with emotional and behavioral 
problems and a control group of adolescents from the community. At discharge, roughly 90% of 
the adolescents from the residential center were rated “moderately” or “much improved”. 
Although the ratings diminished somewhat at the follow-up periods, the adolescents still 
demonstrated fewer severe problems than the comparison group. Gamboa (1974) assessed 116 
children and adolescents admitted to a residential treatment center in Kentucky. Findings 
indicated that the treatment facility was effective in reducing difficulties in personal, school, and 
family areas. Unlike in other studies, these gains were maintained at a 6 month follow up. 
Palmer (1974) examined the effectiveness of a residential program compared to a community-
based treatment group. The RTC was largely based on behavioral principles. The outcome 
criterion was recidivism. The results indicated that 58% of the juveniles in the residential group 
were re-arrested, compared to 94% of the adolescents in the community-based treatment 
group.  
In another early study, researchers followed 51 children discharged from an RTC. Results 
indicated that at follow up, only 30% of the children met the criteria for a positive outcome: less 
than 3 out-of-home placements after discharge, absence of severe psychiatric or legal problems, 
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and absence of psychiatric hospitalization. Those children that were considered to have a 
positive outcome were generally younger and less severely disturbed at admission. As should be 
apparent, the criteria for “success” in this study was set relatively low (Lewis, Lewis, Shanok, 
Klatskin, & Osborne, 1980). Gilliland-Mallo and Judd (1986) conducted a similar study with 
adolescents in an RTC in Colorado. They found 62% of their sample met criteria for a positive 
outcome: placement in a family home, foster care, group home, or some other residential 
facility. An unsuccessful outcome was defined as placement in detention center or termination 
of a placement. The authors also noted several variables that were related to success: race 
(white versus other), absence of court involvement prior to admission, absence of drug abuse 
history, and family involvement in treatment.  
In another study, researchers followed adolescents who had either been involved in a 
therapeutic day school or a residential program. The authors reported that, 10 years later, there 
were no notable differences based on placement (day school versus residential). Overall, nearly 
two-thirds of the participants were “better adjusted” at follow-up. The authors noted that, in 
general, the participants who were the least disturbed at admission were functioning best at 
follow-up (Erker, Searight, Amanat, & White, 1993). Burks (1995) conducted a 6 month follow-
up study of children in an RTC and found that 50% achieved positive outcomes at follow-up.  The 
authors noted that the stability of the post-treatment placement was most strongly related to 
post-discharge functioning.  
Leichtman, Leichtman, Barber, and Neese (2001) conducted 3- and 12-month follow up 
evaluations of 123 adolescents from an RTC in Kansas.  The authors reported that 79% of the 
adolescents made reliable improvements in general functioning and 43% made improvements 
on a self-report measure of behavioral functioning. Further, these changes were noted and 
maintained at both follow-up periods.  
13 
 
Researchers attempted to create a risk-adjusted outcome assessment of several RTCs 
using existing data from the Public Child and Welfare System in Missouri. In total, 3,759 RTC 
stays were included for 2,784 children and adolescents.  Although the primary focus of the 
research was not obtained, they did report a few concerning findings. For one, over half of the 
youth were admitted for a second residential stay within a year of discharge from their first stay. 
Overall, only around one-fourth of youth were able to be maintained at a single lower level-of-
care placement for the year following discharge (McMillen, Lee, & Jonson-Reid, 2008). 
Pfeiffer and Strzelecki (1990) conducted a meta-analysis of 34 outcome studies of child 
and adolescent RTCs. The authors suggested that individualized treatments and client 
involvement in aftercare predicted positive treatment outcomes. The authors also stated that 
positive treatment outcomes were more likely for clients who had less severe, nonorganic 
symptoms, clients without antisocial features, and clients who had “healthier” families. In 2005, 
Hair published a comprehensive literature review on residential outcomes studies from 1993 to 
2003. The researcher concluded that residential treatment is generally effective at reducing 
symptomology and improving behavioral functioning, although these positive treatment effects 
are not always maintained once clients return to less restrictive environments. Based on the 
review, the researcher identified several factors that are potentially related to positive 
treatment outcomes including family involvement in treatment, stable aftercare setting, 
aftercare support for the youth and their families, shorter lengths of stay in RTCs, academic 
success while at the RTC, and successful completion of the RTC program. Handwerk et al. (2006) 
also suggested that females may have a more favorable response to long-term residential 
treatment than males.  
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Psychotropic Medications 
Unfortunately, there is little to no research on the effectiveness of psychotropic 
medications with adolescents in RTCs (Shoaf, 2004). Although more studies are being conducted 
with adolescents in general, these studies are almost exclusively limited to outpatient settings 
with small sample sizes, narrow diagnostic criteria, and are of short duration (McCellen & Werry, 
2003; Thomas & Penn, 2002). A brief review of psychotropic medications studied for use with 
the general child and adolescent population will be described here. For a more thorough review 
see Soller, Karnik, & Steiner (2006).   
Stimulants. Several stimulant medications have been given FDA approval for the 
treatment of ADHD including the amphetamines Adderall and methylphenidates such as 
Concerta, Dexedrine, and Ritalin. Although not a stimulant, atomoxetine hydrochloride 
(Strattera) has also received FDA approval (U.S. Food and Drug Administration [FDA], 2009). 
Stimulant medication has generally been found to be an effective treatment for ADHD. 
In a combined evaluation of over 160 controlled trials of stimulant medication, 65% to 75% of 
children and adolescents diagnosed with ADHD demonstrated improvements. In addition to 
core symptoms of ADHD, stimulant medications have also been shown to be partly effective at 
reducing aggressive behaviors (McCellen & Werry, 2003).  
In one of the largest studies to date in the area of pediatric psychopharmacology 379 
children were randomly assigned to one of several treatment conditions including a behavioral 
therapy intervention, stimulant medication, and both behavioral therapy and stimulant 
medication. Results generally indicated that regularly monitored medication management was 
superior to all the other conditions, although the medication combined with behavioral 
interventions did yield a few additional areas of improvement (Jensen et al., 1999). 
15 
 
A meta-analysis conducted on 28 studies (from 1970 to 2001) found that stimulant 
medication can be effective at treating child and adolescent clients with co-occurring ADHD and 
aggressive behaviors (such as those common in Conduct Disorder). A combined effect size of 
0.84 was reported (Steiner, Saxena, & Chang, 2003).  Another meta-analysis found that 
stimulant medications were equally effective at treating ADHD-related aggression and core 
ADHD symptoms, but only if Conduct Disorder was not also present (Connor, Glatt, Lopez, 
Jackson, & Melloni, 2002). Another study found some support for stimulant medication on 
improving social functioning in adolescents with overly aggressive behaviors (Pappadopulus, 
Guelzow, Wong, Ortega, & Jensen, 2004). However, there has been some concern that stimulant 
medications may actually increase conduct disorder-related behaviors in adolescents without 
ADHD (Klein et al., 1997).  
It should be noted that the overwhelming majority of studies done on stimulant 
medication are short term trials. That being said a few longer-term studies have been conducted 
and have generally found continued positive effects of stimulant medication for ADHD and 
related symptoms so long as the medication continues to be taken (Jensen et al., 2001). 
Several side effects have been reported for adolescents taking stimulant medication 
including over half of participants of one study reporting insomnia, and several others reporting 
nausea, headaches, and irritable mood. A small percentage also developed tics and mild weight 
loss (Barkley, McMurray, Edelbroch, & Robbins, 1990). Other side-effects, albeit rare, include 
psychosis. One study found that 6% (n = 9) of children treated with stimulant medication at one 
outpatient clinic in Canada developed some form of psychotic symptom (Cherland & Fitzpatrick, 
1999).  
 In 2006 The FDA recommended a warning label be placed on stimulant medications due 
to concerns of cardiovascular risks. This warning came after studies revealed that taking 
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stimulant medication can substantially increase heart rate and blood pressure, conditions that 
can lead to severe consequences, including death. The FDA’s Adverse Event Reporting System 
(AERS) documented 25 cases of sudden death potentially resulting from stimulant medication; 
of these 25 deaths 19 were children or adolescents (Nissen, 2006).  
Antidepressants. Selective Serotonin Reuptake Inhibitors (SSRIs) are generally 
considered the frontline choice of antidepressant medication.  Currently, only fluoxetine (e.g., 
Prozac) has been FDA approved for the treatment of pediatric Major Depressive Disorder. 
Fluoxetine, sertaline, and fluvoxamine are approved for pediatric OCD. SSRI medications have 
not been approved by the FDA for any other use. Clomipraramine, a tricyclic antidepressant, has 
also been FDA-approved to treat OCD (FDA, 2009).  
A study done on a medication not approved by the FDA for pediatric use, Citalopram, 
with 174 children and adolescents (ages 7 to 17) found in an 8-week study that the majority of 
participants showed significant decreases in depressive symptoms. The authors reported an 
effect size of 2.9. However, Rhinitis, nausea, and abdominal pain were side effects reported in 
more than 10% of participants (Wagner et al., 2004). 
A few studies have been done comparing the effectiveness of psychotherapy and 
psychopharmacological interventions. Dubicka and Goodyer (2005) highlighted research that 
suggested CBT may be an effective treatment option for adolescents suffering from mild to 
moderate depression but may not be particularly effective, without psychotropic medication, 
for adolescents with severe depression.  However, based on the results of their study Hamilton 
and Bridge (2006)determined that ongoing SSRI treatment with only episodic supportive 
psychotherapy was not effective at preventing recurrances of Major Depressive Episodes in 
adolescents. They suggest the need for evidence based psychotherapeutic practices that can 
produce strong therapeutic alliances and ultimately produce longer-lasting change. 
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One of the largest recent studies to evaluate the effectiveness of SSRIs with children and 
adolescents was The Treatment for Adolescents with Depression Study (TADS). The researchers 
claim that TADS is the only controlled study to compare psychotherapeutic and 
psychopharmacological approaches for adolescent depression.  The study consisted of a 
multisite investigation of 439 adolescents suffering from depression. Adolescents were split into 
four groups: fluoxetine, CBT, combination, and placebo.  Treatment was delivered over 12 
weeks and overall findings demonstrated an advantage for the combined treatment over 
medication alone. Fluoxetine alone appeared more effective than no treatment. However, there 
was no statistical difference in symptom reduction between the CBT only and placebo groups, 
suggesting that CBT alone was not an effective intervention. The rates for harm-related events 
(such as self-harm and suicidal ideation), physical side effects (e.g., diarrhea, sedation, fatigue), 
and psychiatric side effects (e.g., irritability, mania) were much higher among the fluoxetine 
groups compared to the CBT alone or placebo group. The rates of reporting major aversive 
events increased in all groups when elicited through systematic questioning, although all 
treatment groups experienced an overall decrease in suicidality from pretest to posttest. The 
researchers suggest that the combination treatment approach is ideal for the treatment of 
pediatric depression (Antonuccio, 2008; Dubicka & Goodyer, 2005; Emslie et al., 2006). 
SSRIs are commonly used to help treat a variety of psychological disorders other than 
depression. For example, SSRIs combined with clompiramine have been found to be an effective 
treatment for child and adolescent Obsessive Compulsive Disorder (OCD; Emslie, Walkup, 
Pliszka, & Ernst, 1999), as has the combination of fluoxetine and paroxetine in 60% to 75% of 
children and adolescents  with OCD (Shoaf, 2004). 
Some researchers have suggested that the benefits of SSRIs for adolescents have been 
exaggerated and the adverse affects have been ignored (Jureidini et al., 2004). One study 
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reported that 6 of 7 published randomized trials have found that SSRIs in children produce 
favorable results on at least some measures. However, it was also cautioned that 
methodological issues may have inflated the apparent efficacy of SSRIs. In a study commissioned 
by the FDA, in conjunction with Columbia University, researchers found that only 3 of 15 
randomized controlled trials of newer antidepressants showed more effective results than 
placebo (Antonuccio, 2008).  
A recent meta-analysis was conducted on randomized controlled trial, drug-placebo 
contrast studies on the use of antidepressants in juvenile depression. In total, the analysis 
included data from 30 studies and a total of 3,069 participants. The results demonstrated 
limited effectiveness of antidepressants in children and that antidepressants appear to be 
significantly less effective in treating children than adults. Overall, the researchers found 
minimal differences between different antidepressants, with the possible exception of 
fluoxetine. However, it was noted that the favorability of fluoxetine was largely the result of one 
large randomized trial that had an atypically large separation between treatment group and 
placebo. One additional finding was the overall lack of difference between SSRI and tricylic 
antidepressant effectiveness. However, of the 30 trials only 5 (20%) demonstrated statistically 
significant difference between treatment group and placebo and all 5 were SSRI studies 
(Tsapakis, Soldani, Tondo, & Baldessarini, 2008).  
In a meta-analysis conducted in the 1990s researchers found that, overall, studies on 
the efficacy of antidepressant medications for children and adolescents lacked appropriate 
controls, were prone to experimental bias, had problematic selection criteria and outcome 
rating systems, small sample sizes, and a poor accounting of potentially confounding variables. 
In fact, the researchers noted a concerning inverse relationship between positive findings and 
the use of adequate experimental controls (Thurber, Ensign, Punnett, & Welter, 1995). Shoaf 
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(2004) also pointed out that research on adolescent antidepressant medication has shown an 
increasingly high placebo response rate.  
There is concern that antidepressant medication may actually worsen or exacerbate 
psychological and psychiatric symptoms. For example, one study found that 3% to 6% of 
adolescents on SSRIs developed manic symptoms (Emslie & Mayes, 1999). This risk for SSRI-
induced manic symptoms have also been found elsewhere (e.g., Preda, MacLean, Mazure, & 
Bowers, 2001). Additionally, common side-effects of SSRIs include insomnia, fatigue, agitation, 
gastrointestinal problems, sexual problems, decreased appetite, and possible growth 
suppression in children (Antonuccio, 2008; Lakhan & Hagger-Johnson, 2007). When coupled 
with other medications, SSRI use may have other risks, including an increased risk for Serotonin 
Syndrome (or Serotonin Toxicity), which is caused by excessive accumulation of serotonin in the 
body and can result in cognitive effects (e.g., mental confusion, hypomania, hallucinations), 
autonomic effects (e.g., shivering, sweating, tachycardia, nausea), and somatic effects (e.g., 
muscle twitching, tremors). In some cases, Serotonin Syndrome can be lethal (Dvir & 
Smallwood, 2008).  
In 2003, the FDA released a warning that certain antidepressant medications may 
increase suicidality among adolescents diagnosed with depression and in 2004 required that 
warning labels be placed on 10 antidepressant medications. This warning came after evaluating 
24 trials that included over 4,400 depressed children and adolescents. The rate of suicidality was 
4% in treatment groups compared to 2% in the placebo groups. This issue remains controversial 
and debate continues over the significance of these findings. Additionally, many point out that 
SSRI medication appears to reduce overall suicide rates (Dubicka & Goodyer, 2005; 
Pappadopulus et al., 2004; Soller et al., 2006). Others have raised concerns that the use of the 
warning label may actually increase suicide rates in children as parents and treatment providers 
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become more reluctant to provide antidepressants to children who are in need. For example, 
Lineberry, Bostwick, Beebe, & Decker (2007) cited a correlational relationship between a 17% 
increase in child suicide rates and a 17% decrease in antidepressant prescribing. This finding is in 
contrast with the majority of findings that suggest an overall dramatic increase in psychotropic 
medications in children and adolescents (Antonuccio, 2008). 
Neuroleptics (Antipsychotics). Despite the fact that approximately one-third of 
individuals with Schizophrenia experience an adolescent onset and that those with adolescent 
onsets tend to have more severe forms of the disorder, individuals under the age of 18 are 
commonly excluded from pharmacological treatment trials (Ross, 2008).  Only a few 
antipsychotic medications have received FDA approval for pediatric populations.  The only first-
generation, or typical antipsychotic medication approved for minors is lamotrigine (Lamictal) for 
the treatment of seizures.  A few second generation, or atypical antipsychotics have received 
FDA approval. Aripiprazole (Ability) and Risperidone (Risperdal) have been approved to treat 
Schizophrenia in adolescents ages 13 to 17 and for the treatment of manic or mixed episodes of 
Bipolar Disorder I for ages 10 to 17. In addition, Risperidone has been approved to treat 
irritability associated with Autism for children 5 to 16 (FDA, 2009). 
Castro-Fornieles et al. (2008) published results from a naturalistic longitudinal study of 
antipsychotic medication use among adolescents experiencing a first episode of psychosis. Their 
study included 110 adolescents (mean age = 15.5) recruited from adolescent psychiatry units at 
six university hospitals and who were monitored at baseline, 6 months, and 1 year. Their results 
found that three of the second generation antipsychotics: resperidone, quetiapine, and 
olanzapine were the most commonly prescribed.  Clozapine was the most common second 
choice after other medications were shown to have limited success. Results indicated that all 
three antipsychotics resulted in positive effects on all outcome variables, with the exception of 
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resperidone in treating negative symptoms of psychosis. The authors suggested that 
resperidone may actually increase negative symptoms (e.g., hypokinesia and akinesia) as a 
medication side-effect.  Weight gain was also a commonly observed side-effect, especially for 
olalzapine. The authors noted that the weight gain observed in their study was greater than that 
commonly reported in more short-term trials. They caution that long-term use of these 
antipsychotics may place children at an increased risk for insulin resistance, diabetes, 
hypertension, or cardiovascular disease. Resperidone was noted to cause more neurological 
side-effects. It should be noted that that overall neither the doctors nor patients reported that 
the observed side-effects caused marked disturbance in everyday life. This study is 
advantageous compared to other studies in that it observed long-term effects of the 
medication. Limitations include the lack of randomized samples or controls, and selection-bias 
for the different medications as the study was naturalistic. 
Ross (2008) reported the findings of two recent studies on the effectiveness of 
antipsychotics with children and adolescents. The combined results suggested that by six weeks 
participants in placebo groups had a 22% symptom reduction while participants in various 
medication groups (molindone, olanzapine, risperidone, and aripiprazole) had symptom 
reductions ranging from 23% to 30%, demonstrating a relatively low treatment effect size. 
Furthermore, across treatment groups roughly 50% of participants demonstrated no positive 
responses to medication treatment. Side-effects observed included akathisia, extrapyramidal 
symptoms, somnolence, and tremors.  Weight gain was particularly prominent in the olanzapine 
group, but also present in the risperidone group. Olanzapine also had several other observed 
side-effects including changes in heart-rate (i.e., elongated QTc intervals), and increased levels 
of total cholesterol.  
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DelBello, Versavel, Ice, Keller, and Miceli (2008) conducted a study to examine the 
tolerability of ziprasidone (Geodon) in 63 children and adolescents with Bipolar Mania, 
Schizophrenia, or Schizoaffective Disorder. The purpose of the research was to evaluate the 
tolerability of the drug at two fixed doses: 80mg or 160mg. Flexible dosing (20mg to 160mg) was 
included after initial evaluation of the fixed dosing levels.  Although efficacy was not the focus of 
the study, the researchers commented that ziprasidone was generally effective with overall 
symptom reduction. However, side-effects such as sedation, somnolence, headaches, and 
nausea were observed in 20% to 30% of participants in both the fixed-dosage and flexible-
dosage phases. Movement disorders were prevalent in 22% of participants in the fixed dosage 
condition and only reduced to 16% when flexible dosing was allowed. Over a third of 
participants gained greater than or equal to 7% of their baseline weight, a finding that is 
generally higher than those reported with adults on ziprasidone.  The authors also noted that 13 
participants experienced serious symptoms (e.g., suicidal ideation, exacerbation of mania or 
hallucinations); however, the authors attributed this finding to limited effectiveness of 
ziprasidone in treating these diagnostic-consistent symptoms as opposed to medication side-
effects.  
A study conducted in Germany on the long-term weight gain potential of three 
antipsychotic medications found that adolescents on all three medications experienced 
significant weight gain, greater than that typically reported for adults.  After 45 weeks the 
average weight gain was 20.9 pounds for clozapine, 15.9 pounds for risperidone (e.g., Risperdal), 
and an alarming 35.7 pounds for olanzapine (e.g., Zyprexa). Limitations of this study included an 
inability to rule-out weight gain as the result of previous medication treatment, small sample 
sizes, and a lack of a control group. The lack of control is particularly noteworthy considering 
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that the adolescents being observed were in a long-term inpatient facility, most of which do not 
allow for high levels of physical activity (Fleischhaker et al., 2008). 
Antipsychotic medications are commonly used to treat conditions other than psychotic 
disorders. Several published reviews have found antipsychotics to be efficacious in reducing 
symptomology associated with a variety of disorders including Bipolar Disorder, Pervasive 
Developmental Disorder, Autism, and Tourette’s Syndrome, and probably efficacious in treating 
ADHD, Conduct Disorder and aggression, and Mental Retardation. Overall, the studies reviewed 
found positive results, typically in reduction of aggressive behaviors, tics, self-injurious 
behaviors, and positive symptoms of psychosis. However, neuroleptics are known to cause a 
wide variety of side-effects including weight gain, extrapyramidal symptoms or movement 
disorders including tardive dyskinesia, metabolic conditions, and may trigger additional 
psychotic or manic symptoms. Furthermore, it should be noted that many of the published 
studies were conducted in the 1980s, with small sample sizes and open trials. Several 
researchers have cautioned that more current and empirically sound research is needed (Castro-
Fornieles et al., 2008; Cheng-Shannon et al., 2004; DelBello et al., 2008; Fleischhaker et al., 
2008; McCellen & Werry, 2003; McCracken et al., 2002; Robinson, Woerner, Delman, & Kane, 
2005; Soller et al., 2006). 
Mood Stabilizers/Anticonvulsants. The use of medications as mood stabilizers in 
adolescent populations has increased, likely in response to the increase in adolescents being 
diagnosed with Bipolar Disorder (McCellen & Werry, 2003). Lithium remains the primary 
treatment of choice for pediatric Bipolar Disorder and is currently the only non-antipsychotic 
medication approved to treat Bipolar Disorder (FDA, 2009). As Pappadopulus et al. (2004) 
pointed out, despite the fact that Lithium has been given FDA approval for the treatment of 
Bipolar disorder in adolescent populations there is a surprising lack of empirical support for its 
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use. Furthermore, like neuroleptics, the small numbers of studies that have been conducted on 
mood stabilizers were generally done in the 1980s.  
Recent research on the effectiveness of Lithium has been mixed. In a placebo controlled 
study on Lithium use for adolescents diagnosed with primary mood disorders and secondary 
substance dependency, Geller et al. (1998) found that those in the Lithium condition had better 
scores on a global assessment measure. Additionally, Lithium appeared helpful in reducing 
cravings related to substance abuse. However, no difference was found between Lithium and 
placebo on manic symptoms. In two studies published in 2001, the positive therapeutic effects 
of Lithium were significantly reduced once augmented antipsychotic medications were 
discontinued (Kafantaris, Coletti, Dicker, & Padula, 2004). 
 Kafantaris et al. (2004) published what is reported to be the first placebo-controlled 
study on the efficacy of Lithium in treating adolescents with short term mania. In the study all 
participants (N = 40) were placed on Lithium for at least four weeks, and then randomly 
assigned to continue on Lithium or placebo during a 2-week double-blind, placebo-controlled 
phase.  Results from the initial phase of treatment were positive and indicative of a significant 
decrease in symptomology with minimal side-effects. However, results during the subsequent 2-
week double-blind phase indicated that over half (57.5%) of participants experienced 
exacerbated symptoms with no statistical difference noted between the treatment and placebo 
group.  In fact, 11 of the 40 subjects terminated after 1 week of the double-blind phase due to 
clinically significant exacerbation of symptoms. Of the participants who remained on Lithium 
during the double-blind phase, less than half sustained the positive response noted in the initial 
open-trial phase. One possible explanation for the exacerbation of symptoms noted in the 
double-blind phase is that the majority of adolescents included in the trial were initially involved 
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in inpatient treatment, but most were released from the hospital by the time of the double-
blind phase and therefore exposed to psychosocial stressors.  
Lithium, as well as other mood stabilizing drugs, are known to cause several side-effects. 
The most common side-effects noted for Lithium are gastrointestinal problems, polyuria, 
polydipsia, enuresis, dizziness, weight gain, and fatigue. More severe side-effects that occur 
include hypothyroidism and cardiac conduction abnormalities. Additional side-effects have been 
noted when Lithium is used with other medications. Overall, side-effects for Lithium and other 
mood stabilizers are common, but generally mild to moderate, although dangerous and even 
fatal side-effects can occur (Lopez-Larson & Frazier, 2006).  
 Research on other medications for the treatment of adolescent Bipolar Disorder has 
been conducted. Dineen Wagner et al. (2002) evaluated the effectiveness of divalproex sodium 
(Depakote) in 40 children and adolescents ages 7 to 19 with manic, hypomanic, or mixed-
episode Bipolar Disorders.  Slightly over half of participants demonstrated a positive response to 
the medication. Side-effects were generally rated mild to moderate and included nausea, 
vomiting, diarrhea, and somnolence. The study was limited by a high drop-out rate.  
In another study, researchers evaluated the efficacy and tolerability of quetiapine 
(Seroquel) and divalporex (DVP; iDepakote) in treating acute mania in adolescent Bipolar 
Disorder. The sample consisted of 30 hospitalized adolescents ages 12 to 18. Results from the 6-
week trial suggested that the drugs in combination produced greater symptom reduction than 
divalporex combined with placebo. The most common side-effects in both treatment groups 
were sedation, nausea, headaches, weight gain, and gastrointestinal irritation, with all side-
effect severity ratings between mild and moderate. Sedation was the only side-effect more 
prominent in the combined treatment group. Advantages of this study include the double-blind 
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design and use of placebo. Limitations of this study include its short duration and small sample 
size (DelBello, Schwiers, Rosenberg, & Strakowski, 2002). 
 Mood stabilizers have also been used to treat other conditions. Silva, Munoz, and Alpert 
(1996) conducted a meta-analysis on the use of the anticonvulsant medication carbamazepine 
and found some support for its use in adolescents diagnosed with ADHD. A study done with 40 
adolescents diagnosed with conduct disorder found that Lithium helped improve judgment and 
decrease overt aggression. However, several side effects were also common (Malone, Delaney, 
Leubbert, Cater, & Campbell, 2000). Soller et al. (2006) reviewed several research findings that 
also suggest that some mood stabilizers (as well as some atypical antipsychotics) may be 
effective in the treatment of Conduct Disorder, especially symptoms of aggression and 
impulsivity. 
Overall, mood stabilizers have been shown to be somewhat effective at reducing mood 
instability, aggressiveness, and impulsivity across various psychiatric disorders. In treating 
Bipolar Disorder, mood stabilizers appear to be more effective when used in combination with 
an antipsychotic.  Several newer mood stabilizing medications have been increasingly used to 
treat adolescent populations, but there is a noted lack of research (Lopez-Larson & Frazier, 
2006). Common side effects include drowsiness, headache, dizziness, ataxia, somnolence, 
nausea, diarrhea, gastrointestinal symptoms, and weight gain. Other concerns include cardiac 
arrhythmias, acute myopia, blood dyscrasias (Carbamazipine), Stevens-Johnson Syndrome 
(Lamotrigine), and panceatitis and liver failure(Valproate). Additionally, there is some worry 
regarding potential birth defects, raising concern when using mood stabilizers for sexually active 
females (Weller, Kloos, Hitchcock, & Weller, 2005).  
Concomitant Medications. Very few studies have been published to examine the safety 
and efficacy of concomitant medication in adults and almost no research has been done with 
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children and adolescents. In adult studies the risk of adverse side effects has been shown to 
increase with the number of concomitant medications, suggesting the need for caution when 
using multiple medications (Safer et al., 2003). Some single study results have indicated that 
methylphenidate and either desipramine or thioridazine may produce modest improvements in 
ADHD symptoms, but may also cause impaired vigilance and other side effects. Combining 
Clonidine with methylphenidate did not produce any improvement over methylphenidate alone 
(Safer et al.).  
Medication Reduction/Discontinuation in RTCs 
A review of the literature yielded only a handful of studies that specifically addressed 
medication discontinuation or reduction in residential settings. A recent study evaluated the 
residential care of 116 children and adolescents originally admitted to a stabilization unit and 
subsequently referred to residential centers or group homes. Seventy-five percent of those 
placed in residential treatment successfully transitioned to community placements. Although 
not the focal point of the study, the researchers commented on medication use as an indicator 
of treatment success. They noted that 53% of the 116 participants were taking one or two 
psychotropic medications at admission, 31% were taking three or four medications, and less 
than one percent was taking five or more.  At the time of admission, only 11 participants were 
on no medication; this was increased to 23 individuals at discharge. The number of medications 
was reduced for 51 of the individuals and only increased for 22 individuals (Page, Perrin, Tessing, 
Vorndran, & Edmonds, 2007).  
 Connor and McLaughlin (2005)conducted a naturalistic observation of the medication 
use of adolescents in a residential treatment facility. None of the adolescents had their 
medications altered for the purpose of the study, but rather based on decisions by a team of 
psychiatrists. The reserachers reviewed the files of all 141 adolescents admitted to the RTC 
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between 1992 and 2001.  Of those, 112 (79%)were admitted on psychotropic medication and 64 
(45%)of those clients were receiving more than one psychotropic medication, with an average of 
2.6 medications. Of the 112 admitted on medication, 74 (66%) youth were discharged on less 
medication while the remaining 34% had no medication reduction from admission to discharge.  
Neuroleptic, antipsychotic, antidepressant, anticonvulsant, lithium, and clonidine use were all 
significantly diminished at discharge, whereas stimulant medication remained constant from 
admission to discharge. The number of adolescents discharged without any medication was 40, 
up from 29 at admission. Only 8 of the individuals admitted without medication were prescribed 
medication at the RTC. The number of adolescents taking concurrent medications dropped from 
78% at admission to 48% at discharge.  These results are encouraging and suggest that 
medication reduction can be very effective, at least in a structured setting.  However, it should 
be noted the majority of clients admitted with psychotropic medications continued to require 
medication treatment at discharge and that no mention was given as to the treatment 
effectiveness of the RTC.  
Handwerk et al. (2008) published a retrospective analysis of the treatment effectiveness 
at a large RTC with specific focus on medication use. The sample included over 1,000 youth at 
the RTC between 2001 and 2004. The average age was 15, mostly Caucasian, and nearly half 
were referred to treatment by their families. At admission 40% of the participants were taking 
medications (60% antidepressants, 42% stimulants, 31% antipsychotics, & 19% mood stabilizers) 
and 18% were taking multiple medications. Youth admitted on medications endorsed more 
distress on self-report measures (including suicidality), had higher average IQ scores, and were 
more likely to be Caucasian than those admitted without medication.  Additionally, youth 
admitted on medication were more likely to exhibit behavioral problems during treatment. Of 
the roughly 60% of youth admitted without medications, nearly 15% were placed on medication 
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during treatment.  At discharge, a total of 26% of youth left the RTC on medications, 80% of 
which were those admitted on medications. The number of youth discharged on multiple 
medications decreased from 18% to 11%. At discharge, there were no differences in medication 
status by ethnicity. Youth discharged on medications tended to be younger, had shorter length 
of stays, and achieved less treatment goals . At follow-up (3 or 6 months) youth admitted on 
medications were more likely to be attending school regularly or have graduated than those 
admitted without medications. The youth who left treatment on medication were more likely to 
have been formally placed in additional out-of-home placements, including other treatment 
facilities.  
 These results suggest that the RTC was sucessful at reducing the rates of medication 
utilization, although this was not stated as a specific goal or intention. The researchers noted 
that youth discharged without medication reached more treatment goals and were more likely 
to suceed post-treatment.  This finding, combined with the finding that youth discharged on 
medication had shorter lengths of stay, may suggest that youth leaving the facility on 
medications were more difficult to treat and/or required a more intensive level of care. It should 
be noted that the rate of medication utilization at admission (40%) of this study is lower than 
other published studies, possibly suggesting some differences in sample characteristics.  
Furthermore, the authors noted that none of the youth at the RTC were diagnosed with 
psychotic disorders. Noted study limitations included the use of archival data, missing data,  and 
a potentially higher functioning RTC population compared to other RTC clients.   
As should be clear, RTCs and psychotropic medications are common and appear on the 
rise. This trend is occurring despite the lack of clear support for either treatment modality. RTC 
treatment appears to produce modest treatment effects, although multiple outside variables 
influence the long-term success.  Research on the use of psychotropic medication for children 
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and adolescents is conflicted at best.  Only a limited number of medications have been FDA 
approved for use in pediatric populations and even those medications appear to produce only 
modest results with risk of side-effects. Furthermore, many questions have been raised 
regarding the methodological integrity of pediatric psychopharmacological research. The lack of 
research done on child and adolescent psychopharmacology is partly due to a lack of funding for 
expensive controlled medication trials in children and a lack of incentive for the pharmaceutical 
industry to develop drugs in pediatric psychopharmacology (Jensen et al., 1999). Of the few well 
controlled studies done, results indicate that the therapeutic benefit is often questionable 
relative to the number of side effects (McCellen & Werry, 2003). 
The lack of research on the effects of psychotropic medications with adolescents in out-
of-home placements is particularly concerning given the severity and complexity of symptoms 
prevalent in the population (Handwerk et al., 2008). Although more studies are being conducted 
with adolescents in general, these studies are almost exclusively limited to outpatient settings 
with small sample sizes (Thomas & Penn, 2002). Furthermore, despite the frequency with which 
residentially placed adolescents are put on multiple medications, few controlled studies have 
assessed for the efficacy and safety of combining two medications and no controlled studies 
were found on the use of multiple medications for children and adolescents (Connor & 
McLaughlin, 2005).  
Purpose of the Current Study 
The use of psychotropic medication is a common component of residential treatment. 
Yet the lack of supportive research and potential risk raises the question of whether 
psychotropic medicine is a necessary component. At the very least, it seems reasonable that 
RTCs evaluate the rate and quantity of psychotropic medications being given to residential 
clients.   
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Some psychiatrists have suggested that prescribers institute a one month observation 
period wherein clients are completely discontinued from all psychotropic medication to 
establish a baseline and assess for clear-cut target symptoms. Then the determination regarding 
the appropriateness of psychopharmacological interventions can be made (Thomas & Penn, 
2002).The purpose of the present study is to evaluate the medication protocol and overall 
treatment effectiveness of an RTC that utilizes this type of observation period.  To the author’s 
knowledge this is the only study done to specifically evaluate a medication reduction protocol at 
an RTC. Analysis will be done using archival data on medication utilization, demographics, and 
symptomology at admission, during treatment, at discharge, and at follow-up. The specific focus 
of the study is to compare the RTC treatment effectiveness between three groups: those who 
were admitted without medication (no medication group), those admitted on medications that 
were subsequently removed during the observation period (discontinued medication group) and 
those admitted on medications that were placed back on medications after the observation 
period (true responder group). A fourth group, those admitted without medication but 
subsequently placed on medications at the RTC, is expected to be too small in number to be 
analyzed separately. Any youth in this fourth category will be included with the true responder 
group. It is hypothesized that no significant differences will be found between the three groups 
on in-treatment, post-treatment, or follow-up indicators of treatment success, thus suggesting 
that the reduction protocol was effective in identifying those who truly require medication to be 
successful and those who are able to reach treatment goals without medication.    
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METHOD 
Setting 
 St. Mary’s Home for Boys is located in the Northwestern United States and is designed 
for adolescent males between the ages of 10 and 17, although a few clients remained at the RTC 
until age 21. The treatment protocol is defined as a Cognitive Behavioral Interpersonal program. 
The treatment team includes trained support staff, master-level therapists and counselors, a 
board certified child and adolescent psychiatrist, a licensed psychologist, and doctoral level 
psychology practicum students. Clients are monitored throughout the day and progress is 
measured via an established token economy level system. Treatment components include 
individual, group, family, and milieu therapy focused on symptom reduction, increased use of 
effective coping skills, improved rational decision making and problem solving, reduction in 
common “thinking errors” or “irrational thoughts”, and increased pro-social behaviors. 
Additionally, specialized treatment protocols exist for clients with histories of sexual offending, 
trauma, drug and alcohol abuse, and fire-setting. An onsite alternative school provides 
educational instruction and assistance and a transitional living program is also located onsite to 
help selected clients better transition back into the general community.  
 Prior to admission extensive biopsychosocial histories are prepared. Within a month of 
admission objective self-report assessment measures, generally administered by doctoral level 
practicum students, and observer report measures are completed for each client. The self report 
measures are the Multidimensional Anxiety Scale for Children (MASC), Minnesota Multiphasic 
Personality Inventory for Adolescents (MMPI-A), and Trauma Symptom Checklist for Children 
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(TSCC).  The Conners’ Parent Rating Scale (CPRS-R:L) is completed by RTC direct-care staff as an 
observer measure. Within the first month each client meets with the RTC’s licensed clinical 
psychologist who reviews all biopsychosocial and assessment information and conducts a clinical 
interview. The psychologist then provides diagnoses based on the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV-TR; American Psychiatric Association, 2000) and 
individualized treatment recommendations.  
 Within the first month of residency each client meets with a board-certified child and 
adolescent psychiatrist. For those admitted on psychotropic medication, the psychiatrist 
initiates the medication observation and discontinuation period. The medication reduction 
protocol was initiated in 2000 due to observed concerns that an alarmingly high percentage of 
adolescents were being admitted on medication and those adolescents appeared to have more 
difficulty with program compliance. The protocol is used for clients admitted with a regimen of 
medication(s) in place. They are first assessed while on medication using standardized symptom 
measures. Then, the psychiatrist initiates the discontinuation period. As medications are being 
discontinued the psychiatrist, as well as direct-care staff, monitor the clients for behavioral, 
emotional, and psychological functioning. The psychiatrist typically meets with the clients 
weekly during the medication discontinuation period and utilizes a modified version of the Brief 
Psychiatric Rating Scale-Extended Version (BPRS-E) to assess for symptomology. For stimulant 
medication, symptoms are monitored with the Conners’ Global Index (not included in this 
study). After roughly a period of one month of discontinued medication the psychologist, in 
collaboration with counselors and mental health therapists, reviews the client’s progress and 
current functioning. If determined that performance is refractory to the RTC interventions the 
client is returned for psychiatric evaluation. The need for medication initiation, modification, 
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reduction, or discontinuation can be revisited at any point during the client’s stay at the RTC (S. 
L. Henry, personal communication, February 27, 2003). 
 Clients are discharged from the RTC on one of three statuses: planned (i.e., successfully 
graduated from the RTC), removed (i.e., removed from the program by an outside agency or 
parent), or terminated (i.e., relocated to an alternative placement after a determination by the 
treatment team that the client is not appropriate for the RTC setting). For the purposes of this 
study, the removed and terminated clients were combined to form an unplanned group. Clients 
are given a planned discharge from the RTC once they have successfully reached their treatment 
goals.  Discharge assessment measures, the same assessments used at admission, are again 
administered to the clients during the final month of treatment to assess for change.  After 
discharge all clients and/or guardians, regardless of discharge status, are contacted by phone for 
a structured follow-up interview at 3 months, 6 months, and 12 months post-discharge.  
Instruments 
Multidimensional Anxiety Scale for Children (MASC; March, 1997). The MASC is designed 
to assess a variety of anxiety symptoms in children and adolescents ages 8 to 19. It consists of 
39 items on a 4-point Likert-scale.   The measure has been well normed. Mean alpha coefficients 
have been reported at .65. The MASC has also demonstrated some internal validity and good 
discriminant validity (Plake, Impara, & Spies, 2003). At the RTC, the MASC is also given at 
admission and discharge. For the current study the four primary clinical scales will be used in 
analyses: physical symptoms, harm avoidance, social anxiety, and separation/panic.    
Minnesota Multiphasic Personality Inventory for Adolescents (MMPI-A; Butcher et al., 
1992). Originally published in 1992, the MMPI-A is the most used and researched personality 
assessment for adolescents (Archer & Handel, 2001). It consists of 478 true/false items and has 
been extensively normed for adolescents ages 14 to 18. Median test-retest reliability has been 
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reported at r = .80 and alpha coefficients for the clinical scales range from .71 to .91 (Plake et al., 
2003). The MMPI-A has also demonstrated good convergent validity when compared to the 
MMPI, the MMPI-II, clinical interviews, and counselor ratings (Cashel, Rogers, & Sewell, 1998; 
Toyer & Weed, 1998). The MMPI-A has further demonstrated good convergent validity with 
several measures and indicators of juvenile delinquency (e.g., Cashel et al., 1998; Morton, Farris, 
& Brenowitz, 2002; Pena, Megargee, & Brody, 1996; Toyer & Weed, 1998). At the RTC, the 
MMPI-A  is administered at admission and discharge.  For the present study, all 10 basic clinical 
scales and the three primary validity scales will be used.  
Trauma Symptom Checklist for Children (TSCC; Briere, 1996). The TSCC is designed to 
measure chronic posttraumatic stress and related psychological symptomology in children and 
adolescents ages 8 to 16. It consists of 54 items answered on a 4-point Likert-scale. It was based 
on a large normative sample. Mean alpha coefficients have been reported at .84. The TSCC has 
also demonstrated moderate correlations with similar measures, providing some evidence for 
convergent validity (Plake et al., 2003). At the RTC, the TSCC is given at admission and discharge. 
For the present study the six primary scales will be included in the analysis: anxiety, depression, 
anger, PTSD, dissociation, and sexual concerns.  
Conners Parent Rating Scale-Revised (CPRS-R; Conners, Sitarenios, Parker, & Epstein, 
1998). The CPRS-R is designed to obtain parent or caregiver report of childhood behavior 
problems, with specific focus on ADHD and common comorbid ADHD symptoms. It can be used 
for children ranging from ages 3 to 17. It consists of 80 items scored on a 4-point Likert scale. 
The revised scales were normed on a sample of over 8,000 children and adolescents in North 
America. Internal consistency has been demonstrated with coefficent alphas ranging from .75 to 
.94 for males. Convergent validity with psychologist or psychiatrist diagnoses have been well 
established (Conners et al., 1998). At the RTC the CPRS-R is completed by trained support staff 
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during the first and last month of treatment for each client.  In the current study the following 
scales will be used: Oppositional, Emotional Lability,Conners’ Global Index,  DSM Inattentive, 
and DSM Hyperactive- Impusive.  
 Brief Psychiatric Rating Scale-Extended Version (BPRS-E; Lukoff, Nuechterlien, & 
Ventura, 1986).  The BPRS-E is a symptom inventory consisting of 24 items answered on a 7-
point Likert-Scale, ranging from “not present” to “extremely severe”.  The extended version is 
modified from the original, developed by Overall and Gorham in 1962. The measure used at the 
RTC is a slightly modified version of the BPRS-E. The first 13 items are done in a semi-structured 
clinical interview format. The remaining 11 items are observer ratings.  Inter-rater reliability has 
been reported for similar versions to range from .80 to .95 (Ligon & Thyer, 2000). Internal 
validity has also been demonstrated (Thomas, Donnell, & Young, 2004). At the residential 
facility, the BPRS-E is administered as directed by the psychiatrist roughly once a week, typically 
for four weeks , during the medication discontinuation period.  It should be noted that stimulant 
medication is monitored via an alternative measure (not included in this study) . For the current 
study, the total score from the first and last BPRS-E administration will be used.  
Average Large minus Continuous Index (LCI). The LCI is an index score developed by the 
the RTC to track the number of large-scale misbehaviors (e.g., violent or criminal acts) versus the 
number of smaller misbehaviors (e.g., talking out in class) exhibited by adolescents while at the 
treatment facility. Scores range from a -30 to +30 and are calculated weekly, with positive scores 
indicating more large scale misbehaviors than smaller misbehaviors. For the current study the 
overall average LCI score will be used.  
Program Compliance Index (PCI). The PCI is an index score developed by the RTC to 
measure adolescents’ level of behavioral compliance with program expectations while at the 
facility. Client behaviors are tracked throughout each day on a token economy card. The points 
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earned are totaled daily and a PCI score is calculated each week. Scores range from 0 to 1000. 
Scores from 101 to 1000 are labeled as Outstanding, scores from 30-100 are Successful, scores 
from 20-29 are Marginal, scores from 10-19 are Troubled, and scores from 0-9 are Critical. Used 
in the current study is the average weekly PCI score while the client was at the RTC.  
Follow-up Questionnaire.  As part of the RTC’s efforts to track outcome data, follow-up 
questionnaires are completed by phone with clients and/or their guardians at 3, 6, and 12 
months post-discharge. The questionnaire consists of a number of items designed to assess 
post-discharge achievement on six domains applicable to all clients (successful living 
environment, successful school involvement, absence of legal problems, absence of substance 
abuse, active use of community resources, and positive consumer satisfaction) and two 
additional domains that are only applicable to certain discharged clients: active work 
participation (applicable if age eligible) and successful specialized program status (applicable to 
those clients involved in either the RTC’s sexual offender and/or fire setter programs).  A total 
treatment effectiveness score is calculated from the follow-up questionnaires, ranging from 1-5, 
with higher scores indicative of greater outcome success. For the present study two domains 
were used:  successful living environment and successful school involvement. In addition, two 
specific questions from other domains were included: arrests and psychotropic medication use.  
The total treatment effectiveness score for the 3 and 6 month follow ups were also made 
available and included in this study.  
Procedures 
Data Retrieval 
General. All data was retrieved from archival electronic databases kept by the RTC. The 
archival data used was gathered by the RTC for purposes of case management and program 
evaluation. Preexisting disclosure agreements for the use of this data for research purposes 
38 
 
were signed by the legal guardians of each client at admission. The data was coded for 
anonymity by staff members at the RTC prior to being received by the primary researcher in 
order to protect client confidentiality and therefore no identifying information was provided to 
the primary researcher.  
 Medication. All information regarding medication at admission, during treatment, and 
discharge was provided to the primary researcher via an electronic database that specified the 
medication, type, and dosage. Medication information from the follow-up questionnaires were 
non-specific (i.e., taking medication or not). For the purposes of this study medications were 
aggregated into general categories of antipsychotics, stimulants, antidepressants, 
anticonvulsants, antihypertensives, and antianxiety/benzodiazepines. Medications used as sleep 
aids (e.g., Benadryl), antihistamines, PRNs (i.e., as needed), or other non-psychiatric medications 
(e.g., Insulin) were not included. In the current study no distinction was made between subtypes 
of these classifications (e.g., typical versus atypical antipsychotics, SSRI antidepressants versus 
SNRI or TCA antidepressants).  Strattera was coded as a stimulant medication even though it is 
not classified as such due to its use in treating ADHD. Similarly, although not actually an 
anticonvulsant Lithium Carbonate was coded with the anticonvulsants due to its use as a mood 
stabilizer.  The beta-blocker Propranolol was coded as an antihypertensive. All other 
medications were classified based on the Physician’s Desk Reference (PDR; Thompson Corp, 
2008). See Appendix A for a complete list of the medications and classifications represented in 
this sample.   
 Diagnoses. All diagnoses represented in the sample were based on DSM-IV-TR criteria. 
Diagnostic information was only available for those clients admitted on medication. 
Furthermore, for some participants in the sample only the primary diagnosis was made 
available, whereas others had secondary diagnoses listed as well. Diagnoses were grouped into 
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categories: mood disorders, anxiety disorders, psychotic disorders, disruptive behavior disorders 
(Conduct Disorder and Oppositional Defiant Disorder), ADHD, and other (e.g., Reactive 
Attachment Disorder, V codes, Adjustment Disorder, Substance Abuse/Dependence Disorders).  
 Age. Age at admission information was not available. Therefore, to calculate this the age 
at follow-up was subtracted by the follow-up period (e.g., age at 3 month follow up minus 3 
months) to provide an age at discharge. The age at discharge was then subtracted by the time in 
treatment to arrive at an age at admission. Although the reported mean age at admission is 
considered to be representative, it is an estimate.   
 IQ scores. IQ scores were included in the data for both verbal and non-
verbal/performance intelligence. Verbal intelligence scores were from the Verbal IQ score of the 
Wechsler Intelligence Scale for Children-Third Edition (WISC-III) or Wechsler Adult Intelligence 
Scale-Third Edition (WAIS-III), or the Verbal Comprehension Index Score of the WISC-IV.  
Similarly, non-verbal/performance intelligence scores were either from the Performance IQ 
score of the WISC-III or WAIS-III, or the Perceptual Reasoning Index score of the WISC-IV.  
Analysis 
Preliminary analysis  
Missing data. Due the fact that the data used was both archival and longitudinal, a large 
amount of missing data was expected. A priori post-hoc power analysis was conducted using the 
software program G*power 3 (Faul, Erdfelder, Lang, & Buchner, 2007) and indicated that the 
current sample sizes were large enough to provide for adequate power (.80 or greater). 
Therefore, no data imputation methods were used. As such, n sizes vary from one indicator to 
another for both descriptive and outcome data.  
Outliers. All continuous variables were analyzed for outliers by standardizing scores into 
Z scores. Any data point that was greater than or equal to ± 3.0 (standard deviations) was 
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considered an outlier. Visual inspection of those outliers identified six data entry points that 
were clearly data entry errors and because raw scores were not available to the primary 
researcher mean substitution was used to replace those entries. The remaining outliers were 
changed to the closest value within three standard deviations.   
Normality. The Kolmogorov-Smirnov and Shaprio-Wilk statistics were used to assess for 
univariate normality. The majority of scales were positively skewed to varying degrees. 
However, analysis of variance is generally considered robust to violations of normality and 
therefore data transformations were only used for one scale, the PCI, which had extreme 
skewness.  
Primary analysis.  
All analysis was done using SPSS. Categorical data was analyzed using Pearson’s chi-
square. Independent and dependent sample t-tests were used for univariate two-group 
comparisons of mean scores. Univariate analysis of variance (ANOVA) was used for all three 
medication status groups (no medication, discontinued medication, true responders) for single-
scale measures. For measures with multiple subscales (i.e., MASC, MMPI-A, TSCC, CPRS-R) 
multivariate analysis of variance (MANOVA) was used prior to univariate analysis for the scores 
at admission. Univariate analysis of covariance (ANCOVA) and multivariate analysis of 
covariance (MANCOVA) were used for the discharge scores, with corresponding admission 
scores as the covariates. Unless otherwise stated, all analyses conducted in the study were 
within acceptable ranges for the assumptions of the statistical test. Due to the number of 
statistical analyses conducted, a conservative alpha level of p = .01 was chosen a priori.  
Participant Characteristics 
 The sample consists of archival data from an RTC for adolescent males. Data available 
from residents discharged from the program between 2002 and 2008 were included in the 
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analysis. It should be noted that 9 individuals were discharged, re-admitted, and discharged 
again between 2002 and 2008, providing two distinct treatment periods. For the purpose of this 
study each stay was considered separately. Therefore, the total sample consists of 217 distinct 
individuals, with 9 having two entries for a total sample size of 226 admissions. For those who 
were re-admitted to the RTC, certain demographic information (such as ethnicity and IQ scores) 
was only included once.  
 Age at admission ranged from 10 to 18 with an average of 14.50 (SD = 1.41; n = 200). 
Information on ethnicity was available for 184 individuals. Of those, the ethnic composition was: 
73% Caucasian, 8% Hispanic, 7% Native American, 7% Biracial/Other, 5% African 
American/Black, and 1% Asian/Pacific Islander.  Verbal Intelligence scores averaged 92.97 (SD = 
10.75, n = 144) and non-verbal/performance intelligence scores averaged 96.35 (SD = 12.94, n = 
135). Information on fire setting and sexual offending were available for 185 clients. Of those, 
39% (n = 72) were deemed to have problems with fire setting and 29% (n = 54) had problems 
related to sexual offending or sexual aggression (adjudicated or otherwise).  
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RESULTS 
Admission 
Medication 
 Of the 226 RTC admissions, 145 (64%) adolescents were admitted on at least one 
psychotropic medication.  Of those, 34 (23%) adolescents were taking two medications, 36 
(25%) were taking three, 19 (13%) were taking four, 6 (4%) were taking five, 4 (19%) were taking 
six, and one adolescent was admitted on eight medications. The average number of medications 
was 2.48 (SD = 1.39). Overall, 69% of those admitted on a medication were taking at least two, 
with over 20% taking four medications or more. Antidepressants were the most commonly 
prescribed medication, followed in order by stimulants, antipsychotics, anticonvulsants, and 
antihypertensives. Only two individuals were admitted on a Benzodiazepine. Stimulant 
medications were the most commonly prescribed stand-alone medication (n = 19), followed by 
antidepressants (n = 16). The most common co-occurring medications were stimulants and 
antidepressants (n = 56), antipsychotics and antidepressants (n = 45), and stimulants and 
antipsychotics (n = 37).  
Diagnoses 
 Diagnostic information was only available for those clients either admitted or placed on 
medication at the RTC (n = 149, 1 missing). The most common category of diagnosis was 
disruptive behavior disorders (79%, n = 117), followed by ADHD (18%, n = 27), anxiety disorders, 
(17%, n = 25), other diagnoses (10%, n = 14), and mood disorders (9%, n = 13). Only one 
participant was identified as having a psychotic disorder. Due to problems with data collection, 
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the diagnostic information presented here is considered limited and an underrepresentation of 
the total diagnoses present within the population.  
Symptomology 
 Medication admission status. A series of MANOVAs were done comparing those 
admitted on medication with those not admitted on medication across the four objective 
symptom measures. The first MANOVA was used with the four scales (physical symptoms, harm 
avoidance, social anxiety, separation/panic) of the MASC as the dependent variables. The results 
of the MANOVA was not statistically significant (Wilk’s Λ = .93, F(4, 166) = 3.24, p = .014) at the 
.01 level, but was significant at the .05 level. For the MMPI-A, initial examination of the 
correlation matrices revealed several non-significant correlations amongst the 3 validity and 10 
basic clinical scales. Those scales that had non-significant correlations with two or more scales 
were removed from the analysis, leaving seven intercorrelated scales: hypochondriasis, 
depression, psychopathic deviate, paranoia, psychasthenia , schizophrenia , and social 
introversion . The results of the MANOVA was not statistically significant (Wilk’s Λ = .855, F(7, 
104) = 2.505, p = .019) at the .01 level, but was significant at the .05 level. The remaining scales 
were each examined separately using independent samples t-tests. Results from all six t-tests 
were non-significant at the .01 level, although the K scale and the masculinity/femininity scale 
were significant at the .05 level. For the TSCC, a MANOVA was conducted on the six scales of the 
TSCC (anxiety, depression, anger, PTSD, dissociation, sexual concerns). Box’s test for 
homogeneity of regression slopes was violated and therefore Pillai’s Trace was used instead of 
Wilk’s Lambda. The results of the MANOVA was not statistically significant (Pillai’s Trace = .07, 
F(6, 165) = 2.18, p = .047) at the .01 level, but was significant at the .05 level. For the CPRS-R, a 
MANOVA was done on five scales (oppositional, emotional lability, Conners’ Global Index, DSM-
IV Inattentive, DSM-IV hyperactive-impulsive). The results of the MANOVA was not statistically 
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significant (Wilk’s Λ = .91, F(5, 143) = 2.69, p = .02) at the .01 level, but was significant at the .05 
level.  
 Overall, none of the comparisons were significant at the more conservative alpha level, 
but each MANOVA would have been significant if the more traditional alpha (.05) was used. 
Examination of means across the various measures indicates that those admitted on 
medications endorsed higher levels of symptoms across the majority of scales.  
 Medication status at RTC. A second set of MANOVAs were conducted comparing 
admission scores on the four symptom measures between the three medication groups (no 
medication, discontinued, and true responder). The results of the MANOVA was significant for 
the MASC scales (Wilk’s Λ = .88, F(8, 330) = 2.81, p < .01, η2 = .06), indicating that the three 
medication groups did significantly affect the combined DV of the four MASC scales; however, 
the effect size was small. Univariate ANOVA and Scheffé post hoc tests were conducted as 
follow up tests. ANOVA results indicated significant differences for the physical symptom and 
separation/panic scales. Additionally, both the harm avoidance and social anxiety scales were 
significant at the .05 level.  Scheffé post hoc results indicate that the true responders group 
endorsed more physical symptoms and separation/panic anxiety than the other two groups. No 
differences were noted between the discontinued and no medication groups. Results of the 
MASC analysis are presented in Table 1.  
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Table 1 
Comparison of Medication Groups at Admission on the Scales of the MASC 
 
 
MASC scales 
(n = 168) 
No 
Medication 
Discontinued 
Medication 
True 
Responders 
   
 
 
M SD M SD M SD F η2 p 
          
Physical Symptoms 48.27 11.16 52.73 12.50 59.95 13.65 10.37** .11 < .001 
Harm Avoidance 44.12 11.23 46.42 10.31 49.55 9.63   3.13* .04     .046 
Social Anxiety 47.19 11.75 51.07 11.73 54.34 11.79   4.64* .05     .013 
Separation/Panic 51.63 14.54 54.09 13.64 61.11 16.70   4.98** .06     .008 
Note: MASC = Multidimensional Anxiety Scale for Children 
*p < .05. **p < .01 
 
For the MMPI-A, a MANOVA was again conducted on the same seven clinical scales, this 
time with the three medication groups as the independent variable. The results of the MANOVA 
was significant (Wilk’s Λ = .76, F(14, 206) = 2.19, p < .01, η2 = .13), but the effect size was small. 
Univariate ANOVA and Scheffé post hoc tests were conducted as follow up tests. ANOVA results 
indicated significant findings for the medication groups on the hypochondriasis, depression, 
paranoia, and psychasthenia scales. The schizophrenia scale was right at the alpha level. It 
should be noted that Levene’s test for equality of variances was violated for the hypochondriasis 
and psychasthenia scales; however, the sample size is considered robust enough to allow for 
cautioned interpretation. Scheffé post hoc results revealed that for each significant scale, the 
true responders group endorsed significantly more symptoms than the no medication group; no 
other differences were significant.  Individual one-way ANOVAs were done on the remaining six 
scales. Results from all six ANOVAS were non-significant at the .01 level.  The 
masculinity/femininity scale was significant at the .05 level.  Results from the MMPI-A analyses 
are presented in Table 2.   
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Table 2 
Comparison of Medication Groups at Admission on the Scales of the MMPI-A 
MMPI-A Scales 
(n = 112) 
No 
Medication 
Discontinued 
Medication 
True 
Responders 
 
 
 
  
M SD M SD M SD   F η2 p 
a 
Hypochondriasis 49.67 9.01 52.74 10.71 59.73 14.30 6.10** .10 .003 
Depression 50.56 10.04 54.10 8.60 58.48 10.83 4.97** .08 .009 
Psychopathic Deviate 59.72 11.56 60.38 11.32 60.22 14.59 0.03 .00 .967 
Paranoia 52.62 9.74 55.72 10.76 63.17 13.57 6.67 .11 .002 
Psychasthenia 46.92 11.95 54.36 14.69 58.83 11.65 6.61 .11 .002 
Schizophrenia 49.59 11.59 54.14 12.66 59.74 13.70 4.81* .08 .010 
Social Introversion 44.77 10.15 49.52 11.83 50.74 11.86 2.73 .05 .070 
b          
L Scale 53.74 11.36 54.20 10.91 52.00 12.37 0.30 .01 .742 
F Scale 54.10 9.04 52.64 9.51 55.17 9.54 0.64 .01 .528 
K Scale 52.87 11.23 49.04 12.50 47.00 11.56 2.04 .04 .135 
Hysteria 50.44 9.54 51.56 9.11 54.22 10.84 1.13 .02 .328 
Masculinity/Femininity 41.23 7.90 45.48 10.10 46.86 11.33 3.14* .06 .047 
Hypomania 56.74 12.67 55.62 10.60 58.52 15.58 0.43 .01 .652 
Note: MMPI-A = Minnesota Multiphasic Personality Inventory- Adolescent Version 
a Scales included in MANOVA analysis. bScales analyzed separately by one-way ANOVAs 
*p  < .05. **p  < .01 
 
The six scales of the TSCC were used in the next MANOVA. Box’s test for homogeneity of 
regression slopes was violated and therefore Pillai’s Trace was used in place of Wilk’s Lambda. 
The results of the MANOVA was not statistically significant (Pillai’s Trace = .11, F(12, 330) = 1.63, 
p = .08).  The five scales of the CPRS-R were included in the final MANOVA and the result was 
not statistically significant (Wilk’s Λ = .88, F(10, 284) = 1.93, p = .04) at the .01 level, but was 
significant at the .05 level.  
 Overall, significant differences were found between the true responder group and the 
other two groups on the physical symptoms and separation/panic scales of the MASC and 
between the true responder group and the no medication group on the hypochondriasis, 
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depression, paranoia, and psychasthenia scales of the MMPI-A.  The schizophrenia and 
masculinity/femininity scales would have been significant at the .05 level.  
In Treatment 
Medication discontinuation period 
A total of 34 participants had a baseline BPRS-E total score available. The overall mean 
was 38.00 (SD = 11.99). For the true responder group the mean was 42.45 (SD = 15.25) and for 
the discontinued group the mean was 35.87 (SD = 9.76). An independent samples t-test was 
conducted and the difference in mean scores between the two groups was not statistically 
significant (t(32) = -1.53, p = .14). A total of 26 participants had at least one additional BPRS 
score available beyond the initial baseline score. The last score available for each of the 26 
participants was used as the final BRPS-E score. The overall mean was 31.00 (SD = 8.25). For the 
true responder group the mean was 32.00 (SD = 7.33) and the discontinued group was 30.63 (SD 
= 8.73). A repeated measures MANOVA was done with the baseline and last BPRS-E scores as 
the within-groups measure; medication status (true responder/ discontinued) was used as a 
between-groups measure. The within-groups comparison was significant (Wilk’s Λ = .73, F(1, 24) 
= 8.93, p < .01, η2 = .27), indicating that the last BPRS-E score was significantly different from the 
baseline score. The average change from baseline to last BPRS-E score was a 7.12 reduction. 
Only 4 of the 26 participants had an increase in BPRS-E scores from baselines to last. The 
between-subjects comparison was not statistically significant (Wilk’s Λ = .99, F(1, 24) = .02, p = 
.90), indicating that there was not a statistically significant difference between the medication 
groups in change on BPRS-E scores from baseline to last.  
An ANCOVA was conducted using medication classes (antipsychotics, stimulants, 
antidepressants, anticonvulsants, antihypertensives) as independent variables. Each variable 
was coded dichotomously (yes/no).  The last BPRS-E score was used as the dependant variable 
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and the baseline score as the covariate. None of the medication classes were significant, nor 
were any interaction effects, suggesting that no differences were present in last BPRS-E scores 
based on medication classes, while controlling for baseline BPRS-E scores.   
These results suggest that participants experienced a decrease in symptoms over the 
medication reduction observation period. No differences were present between the 
discontinued and true responders group or between medication classes. It should be noted that 
the sample size for these analyses were small, which limited the statistical power to detect 
differences.  
Program performance 
Pre-analysis of the Program Compliance Index score revealed extreme positive 
skewness. As such, a logarithm transformation was used. The transformed data was re-analyzed 
and the assumption of normality was met.  Means and standard deviations are reported in the 
original scale. A one-way ANOVA was conducted comparing the three medication groups on 
average PCI score. The ANOVA was significant (F(2, 193) = 28.70, p < .01, η2 = .23), but the effect 
size was small. Scheffé post hoc results revealed that the no medication group (M = 290.25, SD = 
303.93) had significantly higher program compliance scores than the discontinued (M = 111.11, 
SD = 155.77) and true responder (M = 59.93, SD = 55.13) groups. No statistically significant 
difference was present between the discontinued and true responder groups. However, based 
on the RTC categorical levels the discontinued group would be considered outstanding and the 
true responder group successful.  
 A one-way ANOVA was conducted comparing the three medication groups on LCI 
scores. The ANOVA was significant (F(2, 193) = 29.88, p < .01, η2 = .24), but the effect size was 
small. Scheffé post hoc results revealed that the no medication group (M = 1.38, SD = .85) had 
significantly lower LCI scores than the discontinued (M = 2.10, SD = .82) and true responder (M = 
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2.56, SD = .71) groups, suggesting that during treatment the no medication group had fewer 
large scale behavioral problem incidents than the other two groups. No statistically significant 
differences were found between the discontinued and true responder groups. 
Discharge 
Discharge status 
Of the 190 participants with discharge status data available, 146 (77%) had a planned 
discharge from the RTC. Chi-square analysis was conducted on discharge status and the three 
medication groups and found no significant relationship (χ2 = (2, 190) = 1.26, p = .53). 
Time in treatment 
The average length of stay in the RTC was 1.63 years (SD = .78, n = 215). A one-way 
ANOVA was conducted comparing the three medication groups on length of treatment. The 
ANOVA was not statistically significant (F(2, 212) = 2.78, p = .07), indicating that there was no 
difference between the groups on time spent at the RTC.  
Medication 
 Of the 145 participants admitted on medication, 49 (34%) were put back on medication 
by discharge. Additionally, 5 participants not admitted on medications were prescribed 
medication by discharge, for a total of 54 participants discharged on medication (i.e., true 
responders). Therefore, of the total sample (N = 226) 24% were discharged on medication, 
compared to 64% at admission. This constitutes a nearly 63% reduction in number of 
participants on medication. Chi-square analyses were conducted on the overall medication rates 
at admission and discharge and for each medication class. Each of the analyses was significant, 
indicating a statistically significant reduction in the overall number of people taking medications 
and for each separate medication class.  Table 3 lists the results of the analyses.   
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Table 3 
Number of Adolescents on Medication at Admission and Discharge 
Medication Admission Discharge              χ2              φ               p 
Antidepressants 96 22 7.073 .221 .008 
Stimulants 92 26 18.251 .355     < .001 
Antipsychotics 64 15 8.727 .245 .003 
Anticonvulsants 36 5 15.680 .329     < .001 
Antihypertensives 35 9 15.077 .322 < .001 
      
Medication overall 145 54 21.804 .311 < .001 
 
For those discharged on medication 33 (61%) had one medication, 10 (19%) had two, 
and 7 (13%) had three. Two participants were discharged on four medications, one participant 
was discharged on five, and a final participant was discharged on six. Of the four participants 
discharged with four or more medications two had reductions compared to admission, one 
remained the same, and the final participant had one medication added. At discharge, only 20% 
had three or medications, compared to 45% at admission. For those discharged on medication, 
the average number of medications was 1.72 (SD = 1.14), down from 2.48 at admission.  
For those admitted and discharged on medication, 36 (74%) had a decrease in number 
of medications, 11 (22%) experienced no change, and only one participant had an increase. 
Overall, these participants had an average decrease of 1.47 medications (SD = 1.55). Of the five 
participants who started medications at the RTC, four of them were prescribed one medication 
(a stimulant) and the fifth was prescribed two. At discharge, stimulants were the most 
commonly prescribed medication, followed in order by antidepressants, antipsychotics, 
antihypertensives, and anticonvulsants. No individuals were discharged on a Benzodiazepine.  
 An independent samples t-test was done to compare the number of medications at 
admission between the discontinued and true responder group (minus the five participants who 
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started medication at the RTC). Levene’s test for equality of variances was violated; therefore 
the t-test results were interpreted for unequal variances. The t-test was statistically significant 
(t(74.42) = -4.67, p < .01), indicating that the true responders group (M = 3.24, SD = 1.55) were 
admitted on more medications than the discontinued group (M = 2.08, SD = 1.55).  
Symptomology 
A MANCOVA was planned to analyze the scales of the MASC. However, due to violations 
of the homogeneity of regression slopes assumption for three of the four MASC scales, each 
scale was analyzed separately using ANCOVAs.  Homogeneity of regression slopes was analyzed 
again for each separate ANCOVA and the assumption was met for each. ANCOVA results for 
each scale were not statistically significant: physical symptoms scale (F(2, 85) = .82, p = .45), 
harm avoidance scale (F(2, 85) = .36, p = .70), social anxiety scale (F(2, 85) = .19, p = .83), and 
separation/panic scale (F(2, 85) = .17, p = .85).  
For the MMPI-A, initial evaluation of the correlation matrices revealed only six 
intercorrelated scales that met the assumption of linearity for a MANCOVA: hypochondriasis, 
psychopathic deviate, paranoia, psychasthenia, schizophrenia, and hypomania. Evaluation of the 
homogeneity of regression slopes indicated that an interaction effect was present for both the 
psychasthenia and schizophrenia scales. Therefore, the remaining four scales (hypochondriasis, 
psychopathic deviate, paranoia, and hypomania) were included in the MANCOVA analyses, with 
the corresponding admission scores were used as covariates. The MANCOVA was not 
statistically significant (Wilk’s Λ = .73, F(8, 98) = 2.07, p = .046) at the .01 level, but was at the .05 
level. Next, four scales (L, F, and K validity scales and schizophrenia) were evaluated 
independently using ANCOVA analyses with the corresponding admission score as the covariate. 
Each of the ANCOVAs were not statistically significant: L scale (F(2, 53) = .01, p = .99), F scale 
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(F(2, 53) = .39, p = .68), K scale (F(2, 53) = .24, p = .79), and schizophrenia scale (F(2, 53) = 1.22, p 
= .30).  
For the remaining MMPI-A scales, a significant interaction effect was observed between 
medication groups and admission scores on the discharge scores, preventing the use of 
ANCOVAs. Additionally, an inadequate cell size for the true responders group prevented 
analyses of simple main effects at different levels of the covariate. Therefore, admission scores 
were not used as covariates. The depression, hysteria, and social introversion scales were 
intercorrelated and met the other assumptions for MANOVA analysis. The MANOVA was not 
statistically significant (Wilk’s Λ = .91, F(6, 168) = 1.29, p = .27). Separate one-way ANOVAs were 
used for the remaining two scales and neither were significant: masculinity/femininity (F(2, 86) = 
.49, p = .61) and psychasthenia (F(2, 86) = .18, p = .84).  
Pre-analysis for the TSCC scales indicated that the admission sexual concerns scale had a 
significant interaction effect with medication groups on the combined dependant variable and 
was therefore omitted from the MANCOVA. Evaluation of homogeneity of regression slopes was 
re-evaluated with the remaining five scales and the assumption was met. The admission scores 
for the five scales were used as covariates. The MANCOVA was not statistically significant (Wilk’s 
Λ = .88, F(10, 158) = 1.04, p = .41). A separate ANCOVA was conducted on the sexual concerns 
scale of the TSCC, with the corresponding admission score used as the covariate. The results of 
the ANCOVA was not statistically significant (F(2, 87) = 3.20, p = .046) at the .01 level, but was at 
the .05 level. 
For the scales of the CPRS-R, pre-analysis for a MANCOVA revealed a significant 
interaction effect between the admission DSM-IV inattention scale and medication group on the 
combined dependant variable. Therefore, this variable was excluded from the MANCOVA. The 
remaining four scales were re-evaluated and the assumption of homogeneity of regression 
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slopes was met. The results of the MANCOVA was not statistically significant (Wilk’s Λ = .83, F(8, 
136) = 1.71, p = .10). A separate ANCOVA was conducted on the DSM-IV inattention scale, with 
the admission score as the covariate. The assumption of homogeneity of regression slopes was 
analyzed and met. The results of the ANCOVA was not statistically significant (F(2, 74) = .18, p = 
.84).  
Overall, none of the comparisons revealed statistically significant differences between 
the medication groups at the more conservative alpha level set for this study. Unlike the 
admission symptomology analyses, only a few analyses would have been significant at the 
traditional alpha level. This suggests that for these measures of symptomology little, if any, 
differences existed between the three groups at discharge from the RTC. 
Follow Up 
 Follow up data was gathered at 3, 6, and 12 months post discharge. The response rate 
averaged 74%, 54%, and 37% respectively. The frequencies for each follow up period are 
presented in Table 4.  
Medication use 
 At the 3 month follow up, 27% of participants with available data were taking 
psychotropic medications. Nearly 77% of the true responders group was still taking medication, 
17% of the discontinued medication group resumed taking medications, and 9% of the no 
medication group began taking medication.  At 6 months, overall 25% were taking psychotropic 
medications, 50% of the true responder group, 22% of the discontinued group, and 9% of the no 
medication group. At 12 months, the overall number was 22%, with 55% of the true responder 
group, 12% of the discontinued group, and 5% of the no medication group taking medication.  
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Criminal arrests/charges 
Participants were asked about any new arrests or charges since the last observation 
period. A total of 18% acknowledged being arrested or charged between discharge and 3 
months, 19% between 3 and 6 months, and 35% between 6 and 12 months. It should be noted 
that there were some concerns regarding possible respondent confusion over the wording of 
these items, possibly inflating the number of reported arrests. However, it can be concluded 
that 35% of respondents were arrested or changed at least once during the first year post-
discharge. There was no significant relationship between the three medication groups and 
arrests or charges at 3 months (χ2(2, 172) = 1.56, p = .56),6 months (χ2(2, 122) = 2.06, p = .36), or 
12 months (χ2(2, 78) = 3.38, p = .19) post discharge.  
Living environment 
Living environment post-discharge was broken down into three categories: reintegrated 
(living with parent(s), other family member, or independently), improved (living in less 
restrictive structured setting such as therapeutic foster home or independent living program), or 
unsuccessful (living in a more restrictive setting such as a juvenile correctional facility, refusing 
appropriate placement, or ran away). Across observation periods two-thirds to three-fourths of 
participants were able to remain at a less restrictive environment. There was no significant 
relationship between the three medication groups and living environment status at 3 months 
(χ2(4, 179) = 6.09, p = .19), 6 months (χ2(4, 133) = 3.85, p = .43), or 12 months χ2(4, 92) = 2.59, p = 
.63) post discharge. 
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Table 4 
Total Responses for 3, 6, and 12 Month Follow Up Periods.  
  
Follow Up Period 
Follow up Item 3 months 6 months 12 months 
 
Taking Medication 
 
42 (27%) 
 
30 (25%) 
 
16 (22%) 
Total n 162 118 73 
Arrested or Charged 31 (18%) 23 (19%) 27 (35%) 
Total n 172 122 78 
Living Environment    
reintegrateda 84 (47%) 62 (47%) 45 (49%) 
improvedb 40 (22%) 40 (30%) 22 (24%) 
unsuccessfulc 55 (31%) 31 (23%) 25 (27%) 
Total n 179 133 92 
School status    
Regular Edd 61 (34%) 47 (35%) 27 (28%) 
Special Ede 81 (46%) 52 (39%) 38 (40%) 
Not attendingf 35 (20%) 34 (26%) 31 (32%) 
Total n 177 133 96 
Grades    
Average or above 95 (65%) 65 (59%) 38 (49%) 
Below average/failing 52 (35%) 45 (41%) 40 (51%) 
Total n 147 110 78 
aReintegrated = living with parent(s), other family, or independently. bImproved = less restrictive living 
environment (e.g., therapeutic foster home). cUnsuccessful = more restrictive living environment (e.g., 
juvenile correctional facility). dRegular ed = attending or graduated from regular education or GED 
program. eSpecial ed = attending or graduated from special or alternative education program. fNot 
attending = dropped out or repeated suspensions and expulsions.  
 
Academic status 
Participants were asked if they were attending or had graduated from either regular or 
special education. Across observation periods over two-thirds of participants were attending or 
had graduated from regular, alternative, or special education, although the percentage 
decreased at each observation period from 80% to 68%. There was a significant relationship 
between medication group and academic status at 3 months post discharge (χ2(4, 177) = 24.56, 
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φ= 37, p < .01). There was no significant relationship at 6 months (χ2(4, 133) = 5.82, p = .21). At 
12 months, the results of the chi-square was exactly at the significant level (χ2(4, 96) = 13.89, φ = 
.37, p = .01). At all follow up periods, over half of those in the True Responder group were in 
special education classes. The frequencies for the 3 and 12 month follow up periods are 
presented in table 5. 
Table 5 
Educational Status for the Different Medication Groups at 3 and 12 Month Follow Up Periods.  
Medication 
Status 
Regular 
Educationa 
Special 
Educationb 
Not Regularly 
Attendingc 
Grand 
Total 
 3 month follow up  
No medication %  
(n =  64) 
39.1 28.1 32.8 100 
Discontinued %  
(n = 74) 
39.2 45.9 14.9 100 
True responders % 
(n = 39) 
17.9 74.4 7.7 100 
Total %  
(n = 177) 
34.5 45.8 19.8 100 
 12 month follow up  
No medication %  
(n = 25) 
52.0 16.0 32.0 100 
Discontinued  %  
(n = 47) 
23.4 42.6 34.0 100 
True responders  %   
(n = 24) 
12.5 58.3 29.2 100 
Total %  
(n = 96) 
28.1 39.6 32.3 100 
aAttended or completed regular education. bAttended or completed special or alternative education. 
cDropped out or repeated suspensions and expulsions. 
 
School grades 
Participants were asked what grades they were, or had been, earning. At 3 months, 68% 
reported earning average or above grades. That number dropped to 49% by 12 months. There 
was no significant relationship between medication status and school grades at 3 months (χ2(2, 
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147) = 3.44, p = .18), 6 months (χ2(2, 110) = 2.70, p = .26), or 12 months (χ2(2, 78) = .65, p = .72) 
post discharge. 
Combined outcomes 
 In examining each follow up variable separately, the results suggest that around 60% or 
more of participants maintained desirable outcomes throughout the follow up periods, with the 
exception of grades at 12 months post discharge. However, when the follow up variables are 
examined in combination, the results were somewhat less encouraging. At 3 months, 54% had 
no criminal charges or arrests, a less restrictive living environment, were regularly attending or 
had completed school, and were earning average or above grades. At 6 months, that number 
dropped to 46% and at 12 months to 31%.  
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DISCUSSION 
General Findings 
The purpose of the present study was to evaluate the effectiveness of an RTC for 
adolescent males that utilizes a medication reduction protocol. At admission, 64% of 
participants were taking at least one psychotropic medication with over 69% of those taking two 
or more, with an average number of medications at 2.48. The rate of concomitant medication 
use and average number of medications in this sample was higher than the 40% concomitant 
rate and 1.9 average found in the Connor et al. (1998) study. This finding is particularly 
concerning given the lack of research on concomitant medication use, especially considering 
that 20% of those admitted on medication in the current study were taking four or more 
different medications. The overall prevalence of medication use at admission was similar to 
those reported in other RTC studies (Bellonci & Henwood, 2006; Breland-Noble et al., 2004; 
Connor et al., 1998; Najjar et al., 2004; Warner et al., 2004). It is also worth noting that the True 
Responder group was taking more medications at admission.  
As with the Handwerk et al. (2008) study, those admitted on medication tended to have 
higher levels of presenting symptomology, although in the present study these differences were 
not significant at the .01 level.   When the three medication status groups (no medication, 
discontinued, true responder) were compared on admission scores the true responder group 
had higher levels of symptomology than the other two groups across most measures. There was 
a statistically significant difference between the true responder and other two groups on the 
physical symptoms and separation/panic scales of the MASC. The physical symptoms scale is 
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particularly noteworthy, as medication side-effects may have contributed to the increased 
scores for the True Responder group. Additionally, the true responder group had statistically 
significantly higher scores than the no medication group on the hypochondriasis, depression, 
paranoia, and psychasthenia scales of the MMPI-A. Furthermore, several other comparisons 
would have been significant at the .05 level. These results suggest that, consistent with other 
reports, those admitted on medication and, especially those who remained on medication, 
tended to endorse higher levels of symptomology at admission. Although the effect sizes for 
these differences were generally small, the observed differences generally ranged from 7 to 12 
points higher for the True Responder group, a difference that could very well have clinical 
significance.  This finding suggests that those who remained off of medication and those placed 
back on medication were already exhibiting differences before treatment began.  
During the medication reduction period BPRS-E scores at baseline, just prior to the 
medication discontinuation period, were significantly higher than the scores at the last 
evaluation period. This suggests a somewhat paradoxical finding: as participants were taken off 
of their medication, their reported and observed symptoms decreased. The sample size for this 
particular analysis was notably small, thus making it difficult to draw meaningful conclusions 
about this result. Furthermore, the measure used to monitor stimulant medication, the most 
frequent medication type at discharge, was not used in the present study. Complicating 
interpretation even more is that the participants were receiving therapeutic intervention at the 
RTC during this time, which may partially explain the decrease in symptoms. Nonetheless, this 
finding raises questions about the actual impact of these medications. There were no 
statistically significant differences on BPRS-E scores between those placed back on medication 
and those who were not. This is somewhat surprising as the RTC reportedly uses BPRS-E scores 
to aid in determining which participants truly benefit from medication. It may suggest that other 
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factors more heavily contributed to the decision whether to place an adolescent back on 
medication.  
After the medication discontinuation observation period 66% of those admitted on 
medication remained off of medication through discharge. Overall, 24% of the participants were 
discharged on medication, which is similar to the 26% reported by Handwerk et al (2008).  For 
those discharged on medication 74% had the number of medications reduced. Furthermore, 
although not reported in the present study, it is likely that those remaining on medication also 
had dosages lowered.   
Similar to the Handwerk et al. (2008) study, those not taking medication had better in-
treatment success. In the present study those never on medication at the RTC had better 
program compliance and fewer large scale behavioral problems. This may be partially due to the 
fact that the measures used to assess in-treatment success were an average score for the 
participants’ entire length of stay. The use of mean scores for these indicators did not allow for 
assessment of change over time. Considering the findings of symptomology scores at admission 
and discharge, it is possible that the differences in mean scores were the result of the 
Discontinued group and True Responder group having poorer RTC performance at the beginning 
of treatment.  No differences were observed between the medication groups on treatment 
duration or planned discharges. No statistically significant differences were noted on any of the 
discharge symptomology measures. Further, only two analyses, a MANCOVA with select MMPI-
A scales and an ANCOVA with the sexual concerns subscale of the TSCC, would have been 
significant at the .05 level. These findings suggest that any differences in symptomology that 
may have been present at admission were no longer present by discharge.  These results 
indicate that the RTC program equalized symptomology for all residents, regardless of 
medication status. In addition to general RTC treatment effectiveness, another possible 
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explanation for the symptom equalization is that almost all of those admitted on medication 
had their medications reduced or discontinued and, as was seen in the BRPS-E findings, the 
reduction of medication may have some relationship to symptomology. It is also possible that 
medication side-effects were contributing to elevated symptoms at admission. These findings 
are different from the Handwerk et al. study which found that being discharged on medication 
was associated with more treatment failure, including shorter treatment durations and higher 
levels of behavioral and emotional problems at discharge. This disparity may be due to 
differences in sample characteristics. In the Handwerk et al. study 40% of participants were 
admitted on medication, with 18% of those on multiple medications, compared to 64% and 69%, 
respectively, in the current study. Another possible explanation is that the RTC in the current 
study may have been more effective at discontinuing medication, thus reducing any iatrogenic 
medication effects. In the Handwerk et al. study over half of participants admitted on 
medication remained on medication at discharge, compared to only 34% in the current study. 
The differences between the two studies may also be the result of medication protocol, in that 
clients placed back on medication at the RTC in the current study were observed and closely 
monitored for an extended period of time. This observation period provided the prescribing 
psychiatrist with specific and detailed information on observed symptoms, allowing for more 
targeted medication use. Whatever the explanation, it appears that the RTC in the present 
study, with its use of the medication reduction protocol, was more successful at treating those 
who remained on medication.  
At all follow up periods, the overall rate of medication use ranged from 22% to 27%, 
similar to the 24% at discharge. For those discharged on medication 75% continued taking 
medication at 3 months, but this number dropped to 50% and 55% for 6 and 12 months 
respectively. The rates of medication use were between 12% and 22% across follow up periods 
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for those that had their medications discontinued at the RTC. The follow up rates of medication 
use remained low (5% to 9%) for those never on medication at the RTC.  
 For other follow up measures, no differences were observed between the groups on 
arrests or criminal charges. Although there was some concern regarding measurement error for 
this variable, it can be determined that, overall, 35% were arrested or charged within a year of 
discharge. No differences between the groups were present for post-discharge living 
environment either, which is different from the Handwerk et al. (2008) study that found those 
discharged on medications had more formal placements and were more likely to be living in a 
treatment facility. In the present study around 70% of participants were living with parents, 
family, independently, or in a less restrictive structured environment (e.g., therapeutic foster 
home)at each follow up period; the remaining participants had either ran away, were refusing 
placement, or were living in a more restrictive setting (e.g., juvenile correctional facility). The 
70% found in this study is particularly encouraging considering that McMillen et al. (2008) found 
that over half of RTC clients end up being readmitted to an equal or higher level of care 
placement within a year.  
The only follow-up category to have group differences was academic status. The primary 
difference appeared to be that there were far more True Responders in special education across 
all observation periods. Coupled with the finding that stimulant medication was the most 
commonly prescribed medication at discharge, this finding may provide some descriptive 
information about the True Responder group and the nature of their symptoms. Specifically, it 
may suggest that those in the True Responder group were more likely to have organic symptoms 
related to problems with sustained attention and focus. Additionally, at 3 months post-
discharge more participants from the No Medication group were not regularly attending school; 
however, this difference was not present at either 6 or 12 months, due to an increase in non-
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attendance for the Discontinued and True Responder groups.  Overall, 80% of participants were 
either attending or had completed regular or special education at 3 months; this fell to 68% at 
12 months. No differences were observed between the groups on grades earned.  Overall, at 3 
months 65% of participants were earning grades of average or better, but that number was 
down to 49% at 12 months.  
The overall treatment effectiveness of the RTC was generally encouraging. At discharge, 
over three-fourths of participants successfully completed treatment and demonstrated 
reductions in symptomology across multiple measures. The results from the current study at 
discharge were generally more favorable than many previously published studies (e.g., Burks, 
1995; Lewis et al., 1980; Lyons et al., 2001; Rhode et al., 2004). At the follow up periods over 
two-thirds of adolescents maintained positive outcomes on most individual follow up indicators. 
However, the number of adolescents maintaining desirable outcomes across all indicators fell 
below one-third at 12 months. The follow up results were similar to other studies in that the 
positive gains made in treatment tended to diminish somewhat over time (e.g., McMillen et al., 
2008; Palmer, 1974; Weinstein, 1974). This finding emphasizes the need for future research to 
utilize follow up periods of up to at least one year, considering that in the current study many of 
the diminished gains were only present at 12 months.  
Overall, the treatment effectiveness of the RTC was generally similar to or better than 
other published reports.  Almost no differences were observed between those not on 
medication, discontinued from medication, or continued on medication on outcome variables at 
discharge or follow up, suggesting that the RTC effectiveness was equal for all three groups. This 
also suggests that the RTC was successful at correctly identifying those who truly responded to 
medications from those who did not.  The hypotheses that the three groups would fare equally 
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were generally confirmed, except for the No Medication group having higher mean scores on in-
treatment indicators of program performance.  
The most salient findings from this study are that nearly two-thirds of those admitted on 
medication were able to be successfully discontinued from their medication without any notable 
adverse effects and fared just as well as those never on medication in the first place. The 
majority of those placed back on medication had a decrease in number of medications and also 
fared just as well as those not taking medication. Secondly, the observed relationship between 
medication discontinuation and decreased symptoms was surprising. There was not enough 
data in the current study to make meaningful conclusions about this finding, but it warrants 
further evaluation.  
  
Limitations 
The primary limitation of this study is that is based on archival data from one residential 
treatment center. This, in combination with the use of longitudinal data led to a large amount of 
missing agency data.  The use of archival data also prevented the use of other assessment 
measures that may be better suited to measure the variables of interest. For example, including 
assessment measures specifically designed for medication side-effects, such as the Simpson-
Angus Rating Scale (SARS; Simpson & Angus, 1970) or the Abnormal Involuntary Movement 
Scale (AIMS; Guy, 1976), may have provided a more full account of the impact of medication use 
and discontinuation. Also, the absence of the measure used for stimulant medication limited the 
findings related to the medication discontinuation period. Additionally, although the overall 
sample size was adequate for most analyses, the amount of missing data for a few comparisons 
created notably small sample sizes. For example, the lack of diagnostic information prevented 
further evaluation of the relationship between medications, symptoms, and diagnosis. The data 
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that was used was combined from multiple sources within the RTC. Although every effort was 
made to ensure continuity and compatibility of the multiple data sources, possible unknown 
error variables may have diminished the interpretability and generalizability of the results. The 
RTC was only for male adolescents, obviously further limiting the generalizability. The use of a 
more conservative alpha level for this study was appropriate due to the number of analyses 
being conducted. However, this limited the ability to detect differences when they appeared to 
exist, thereby inflating type II error.  
Suggestions for Future Research 
Primarily, it is suggested that future research be done on a planned, a priori evaluation 
of a reduction protocol as opposed to archival data to minimize missing data, ensure that proper 
measures be used for this specific purpose and to allow for a more systematic implementation 
of the protocol. Further, it would be beneficial for future research be done on all sexes. It is 
advised to use a comparison group RTC to better evaluate medication utilization and treatment 
outcomes.  Follow up periods of at least one year should also be used. The potential iatrogenic 
impact of medication use warrants further exploration to better understand the relationship 
between medication use and symptomology, as well as studies on the impact of medication 
discontinuation in general. Ideally, this type of research would focus on the relationship 
between medication and potential side-effects, symptoms, and diagnosis. Lastly, the use of 
random assignment between discontinued and continued medication groups may be considered 
if it can be conducted in an ethically appropriate manner.  
Conclusions 
Despite its limitations, this study demonstrates that the RTC medication protocol was 
highly successful at reducing the number of participants on medication and reducing the 
number of medications for those who continued taking them. Additionally, at discharge and at 
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follow up periods the participants in the current study generally reached and maintained many 
of their treatment objectives, regardless of medication status. This suggests, at a minimum, that 
the medication reductions and discontinuations did not negatively impact client outcomes, and 
perhaps even helped improve them.  The clients at this RTC reached desirable outcomes 
comparable or better than other studied RTC clients, who presumably are continuing to be 
discharged on high rates of medication. There generally appears to be fear among parents and 
treatment providers when it comes to discontinuing medication and far too often providers are 
all too willing to try pharmaceutical intervention, especially with this population. The results of 
this study suggest that RTC treatment can be effective without relying on the common practice 
of alarmingly high medication utilization.  
There is no question that the RTC population is especially challenging to treat and is 
often treatment resistant. Furthermore, there are certainly some adolescents that truly benefit 
from psychotropic medication. However, it is imperative that psychiatric providers demonstrate 
patience and prudence in prescribing and evaluating medication use so that the true benefits 
can be realized while potential adverse effects are minimized.  The common practice of 
prescribing excessive medication to this population appears ineffective and potentially 
dangerous. After all, this type of medication use did not prevent these adolescents from 
requiring residential level-of-care in the first place. A residential setting provides an ideal 
environment to allow for the safe use of a medication reduction protocol where clients can be 
continually observed and monitored over an adequate period of time. These findings lend 
support for other RTCs to utilize some form of discontinuation observation period to better 
determine which adolescents are actually benefiting from medication.  
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